

(1-20); (21-279); (280-366); (367-516); (517-587); (588-640); (641-669)

1. Worm J, Falkenberg K, Olesen J. Histamine and migraine revisited: mechanisms and possible drug targets. *J Headache Pain*. 2019;20(1):30.
2. Heinskou TB, RoCHAT P, Maarbjerg S, Wolfram F, Brennum J, Olesen J, Bendtsen L. Prognostic factors for outcome of microvascular decompression in trigeminal neuralgia: A prospective systematic study using independent assessors. *Cephalalgia*. 2019;39(2):197-208.
3. Heinskou TB, Maarbjerg S, Wolfram F, RoCHAT P, Brennum J, Olesen J, Bendtsen L. Favourable prognosis of trigeminal neuralgia when enrolled in a multidisciplinary management program - a two-year prospective real-life study. *J Headache Pain*. 2019;20(1):23.
4. Hansen TF, Chalmer MA, Haspang TM, Kogelman L, Olesen J. Predicting treatment response using pharmacy register in migraine. *J Headache Pain*. 2019;20(1):31.
5. Chalmer MA, Hansen TF, Olesen J. Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia. *Cephalalgia*. 2019;39(1):38-43.
6. Arnglim N, Hougaard A, Schytz HW, Vestergaard MB, Britze J, Amin FM, Olsen KS, Larsson HB, Olesen J, Ashina M. Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2019;39(4):680-9.
7. Yang Y, Zhao H, Boomsma DI, Ligthart L, Belin AC, Smith GD, Esko T, Freilinger TM, Hansen TF, Ikram MA, Kallela M, Kubisch C, Paraskevi C, Strachan DP, Wessman M, van den Maagdenberg A, Terwindt GM, Nyholt DR. Molecular genetic overlap between migraine and major depressive disorder. *European journal of human genetics : EJHG*. 2018;26(8):1202-16.
8. Ramachandran R, Pedersen SH, Amrutkar DV, Petersen S, Jacobsen JM, Hay-Schmidt A, Olesen J, Jansen-Olesen I. Selective cephalic upregulation of p-ERK, CamKII and p-CREB in response to glyceryl trinitrate infusion. *Cephalalgia*. 2018;38(6):1057-70.
9. Olesen J. International Classification of Headache Disorders. *Lancet Neurol*. 2018;17(5):396-7.
10. Munro G, Petersen S, Jansen-Olesen I, Olesen J. A unique inbred rat strain with sustained cephalic hypersensitivity as a model of chronic migraine-like pain. *Scientific reports*. 2018;8(1):1836.
11. Lebedeva ER, Gurary NM, Gilev DV, Olesen J. Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. *Cephalalgia*. 2018;38(3):561-7.
12. Lebedeva ER, Gurary NM, Gilev DV, Christensen AF, Olesen J. Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. *Cephalalgia*. 2018;38(8):1463-70.
13. Kogelman LJA, Elgaard-Christensen R, Olesen J, Jansen-Olesen I, Hansen TF. Transcriptomic profiling of trigeminal nucleus caudalis and spinal cord dorsal horn. *Brain research*. 2018;1692:23-33.
14. Ghanizada H, Arnglim N, Schytz HW, Olesen J, Ashina M. Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura. *Cephalalgia*. 2018;38(13):1940-9.
15. Falkenberg K, Olesen J. Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. *J Headache Pain*. 2018;19(1):71.
16. Falkenberg K, Dunga BOA, Guo S, Ashina M, Olesen J. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. *J Headache Pain*. 2018;19(1):11.
17. Christensen SL, Petersen S, Sorensen DB, Olesen J, Jansen-Olesen I. Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats. *Cephalalgia*. 2018;38(3):452-65.
18. Chalmer MA, Esserlind AL, Olesen J, Hansen TF. Polygenic risk score: use in migraine research. *J Headache Pain*. 2018;19(1):29.

19. Arngrim N, Schytz HW, Britze J, Vestergaard MB, Sander M, Olsen KS, Olesen J, Ashina M. Carbon monoxide inhalation induces headache in a human headache model. *Cephalalgia*. 2018;38(4):697-706.
20. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letenneur L, Hannequin D, Amouyel P, Boland A, Deleuze JF, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kambouh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL, Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, Smith AG, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Nothen MM, Rossor M, Lupton MK, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee SJ, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JI, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh KH, Cuenca-Leon E, Furlotte N, Kurth T, Ligthart L, Terwindt GM, Freilinger T, Ran C, Gordon SD, Borck G, Adams HHH, Lehtimäki T, Wedenoja J, Buring JE, Schurks M, Hrafnisdóttir M, Hottenga JJ, Penninx B, Artto V, Kaunisto M, Vepsäläinen S, Martin NG, Montgomery GW, Kurki MI, Hamalainen E, Huang H, Huang J, Sandor C, Webber C, Muller-Myhsok B, Schreiber S, Salomaa V, Loehrer E, Gobel H, Macaya A, Pozo-Rosich P, Hansen T, Werge T, Kaprio J, Metspalu A, Kubisch C, Ferrari MD, Belin AC, van den Maagdenberg A, Zwart JA, Boomsma D, Eriksson N, Olesen J, Chasman DI, Nyholt DR, Avbersek A, Baum L, Berkovic S, Bradfield J, Buono R, Catarino CB, Cossette P, De Jonghe P, Depondt C, Dlugos D, Ferraro TN, French J, Hjalgrim H, Jamnadas-Khoda J, Kalviainen R, Kunz WS, Lerche H, Leu C, Lindhout D, Lo W, Lowenstein D, McCormack M, Moller RS, Molloy A, Ng PW, Oliver K, Privitera M, Radtke R, Ruppert AK, Sander T, Schachter S, Schankin C, Scheffer I, Schoch S, Sisodiya SM, Smith P, Sperling M, Striano P, Surges R, Thomas GN, Visscher F, Whelan CD, Zara F, Heinzen EL, Marson A, Becker F, Stroink H, Zimprich F, Gasser T, Gibbs R, Heutink P, Martinez M, Morris HR, Sharma M, Ryten M, Mok KY, Pulit S, Bevan S, Holliday E, Attia J, Battey T, Boncoraglio G, Thijs V, Chen WM, Mitchell B, Rothwell P, Sharma P, Sudlow C, Vicente A, Markus H, Kourkoulis C, Pera J, Raffeld M, Silliman S, Boraska Perica V, Thornton LM, Huckins LM, William Rayner N, Lewis CM, Gratacos M, Rybakowski F, Keski-Rahkonen A, Raevuori A, Hudson JI, Reichborn-Kjennerud T, Monteleone P, Karwautz A, Mannik K, Baker JH, O'Toole JK, Trace SE, Davis OSP, Helder SG, Ehrlich S, Herpertz-Dahlmann B, Danner UN, van Elburg AA, Clementi M, Forzan M, Docampo E, Lissowska J, Hauser J, Tortorella A, Maj M, Gonidakis F, Tziouvas K, Papezova H, Yilmaz Z, Wagner G, Cohen-Woods S, Herms S, Julia A, Rabionet R, Dick DM, Ripatti S, Andreassen OA, Espeseth T, Lundervold AJ, Steen VM, Pinto D, Scherer SW, Aschauer H, Schosser A, Alfredsson L, Padyukov L, Halmi KA, Mitchell J, Strober M, Bergen AW, Kaye W, Szatkiewicz JP, Cormand B, Ramos-Quiroga JA, Sanchez-Mora C, Ribases M, Casas M, Hervas A, Arranz MJ, Haavik J, Zayats T, Johansson S, Williams N, Dempfle A, Rothenberger A, Kuntsi J, Oades RD, Banaschewski T, Franke B, Buitelaar JK, Arias Vasquez A, Doyle AE, Reif A, Lesch KP, Freitag C, Rivero O, Palmason H, Romanos M, Langley K, Rietschel M, Witt SH, Dalsgaard S, Borglum AD, Waldman I, Wilmot B, Molly N, Bau CHD, Crosbie J, Schachar R, Loo SK, McGough JJ, Grevet EH, Medland SE, Robinson E, Weiss LA, Bacchelli E, Bailey A, Bal V, Battaglia A, Betancur C, Bolton P, Cantor R, Celestino-Soper P, Dawson G, De Rubeis S, Duque F, Green A, Klauck SM, Leboyer M, Levitt P, Maestrini E, Mane S, De-Luca DM, Parr J, Regan R, Reichenberg A, Sandin S, Vorstman J, Wassink T, Wijsman E, Cook E, Santangelo S, Delorme R, Roge B, Magalhaes T, Arking D, Schulze TG, Thompson RC, Strohmaier J, Matthews K, Melle I, Morris D, Blackwood D, McIntosh A, Bergen SE, Schalling M, Jamain S, Maaser A, Fischer SB, Reinbold CS, Fullerton JM, Guzman-Parra J, Mayoral F, Schofield PR, Cichon S, Muhleisen TW, Degenhardt F, Schumacher J, Bauer M, Mitchell PB, Gershon ES, Rice J, Potash JB, Zandi PP, Craddock N, Ferrier IN, Alda M, Rouleau GA, Turecki G, Ophoff R, Pato C, Anjorin A, Stahl E, Leber M, Czerski PM, Cruceanu C, Jones IR, Posthuma D,

Andlauer TFM, Forstner AJ, Streit F, Baune BT, Air T, Sinnamon G, Wray NR, MacIntyre DJ, Porteous D, Homuth G, Rivera M, Grove J, Middeldorp CM, Hickie I, Pergadia M, Mehta D, Smit JH, Jansen R, de Geus E, Dunn E, Li QS, Nauck M, Schoevers RA, Beekman AT, Knowles JA, Viktorin A, Arnold P, Barr CL, Bedoya-Berrio G, Bienvenu OJ, Brentani H, Burton C, Camarena B, Cappi C, Cath D, Cavallini M, Cusi D, Darrow S, Denys D, Derks EM, Dietrich A, Fernandez T, Figuee M, Freimer N, Gerber G, Grados M, Greenberg E, Hanna GL, Hartmann A, Hirschtritt ME, Hoekstra PJ, Huang A, Huyser C, Illmann C, Jenike M, Kuperman S, Leventhal B, Lochner C, Lyon GJ, Macciardi F, Madruga-Garrido M, Malaty IA, Maras A, McGrath L, Miguel EC, Mir P, Nestadt G, Nicolini H, Okun MS, Pakstis A, Paschou P, Piacentini J, Pittenger C, Plessen K, Ramensky V, Ramos EM, Reus V, Richter MA, Riddle MA, Robertson MM, Roessner V, Rosario M, Samuels JF, Sandor P, Stein DJ, Tsetsos F, Van Nieuwerburgh F, Weatherall S, Wendland JR, Wolanczyk T, Worbe Y, Zai G, Goes FS, McLaughlin N, Nestadt PS, Grabe HJ, Depienne C, Konkashbaev A, Lanzagorta N, Valencia-Duarte A, Bramon E, Buccola N, Cahn W, Cairns M, Chong SA, Cohen D, Crespo-Facorro B, Crowley J, Davidson M, DeLisi L, Dinan T, Donohoe G, Drapeau E, Duan J, Haan L, Hougaard D, Karachanak-Yankova S, Khrunin A, Klovins J, Kucinkas V, Lee Chee Keong J, Limborska S, Loughland C, Lonqvist J, Maher B, Mattheisen M, McDonald C, Murphy KC, Nenadic I, van Os J, Pantelis C, Pato M, Petryshen T, Quedsted D, Roussos P, Sanders AR, Schall U, Schwab SG, Sim K, So HC, Stogmann E, Subramaniam M, Toncheva D, Waddington J, Walters J, Weiser M, Cheng W, Cloninger R, Curtis D, Gejman PV, Henskens F, Mattingsdal M, Oh SY, Scott R, Webb B, Breen G, Churchhouse C, Bulik CM, Daly M, Dichgans M, Faraone SV, Guerreiro R, Holmans P, Kendler KS, Koeleman B, Mathews CA, Price A, Scharf J, Sklar P, Williams J, Wood NW, Cotsapas C, Palotie A, Smoller JW, Sullivan P, Rosand J, Corvin A, Neale BM, Schott JM, Anney R, Elia J, Grigoriou-Serbanescu M, Edenberg HJ, Murray R. Analysis of shared heritability in common disorders of the brain. *Science (New York, NY)*. 2018;360(6395).

21. Maarbjerg S, Wolfram F, Heinskou TB, Rochat P, Gozalov A, Brennum J, Olesen J, Bendtsen L. Persistent idiopathic facial pain - a prospective systematic study of clinical characteristics and neuroanatomical findings at 3.0 Tesla MRI. *Cephalalgia*. 2017;37(13):1231-40.
22. Munro G, Jansen-Olesen I, Olesen J. Animal models of pain and migraine in drug discovery. *Drug discovery today*. 2017;22(7):1103-11.
23. Lebedeva ER, Kobzeva NR, Gilev DV, Olesen J. The quality of diagnosis and management of migraine and tension-type headache in three social groups in Russia. *Cephalalgia*. 2017;37(3):225-35.
24. Lebedeva ER, Kobzeva NR, Gilev DV, Kislyak NV, Olesen J. Psychosocial factors associated with migraine and tension-type headache in medical students. *Cephalalgia*. 2017;37(13):1264-71.
25. Kogelman LJA, Christensen RE, Pedersen SH, Bertalan M, Hansen TF, Jansen-Olesen I, Olesen J. Whole transcriptome expression of trigeminal ganglia compared to dorsal root ganglia in *Rattus Norvegicus*. *Neuroscience*. 2017;350:169-79.
26. Hansen RD, Christensen AF, Olesen J. Family studies to find rare high risk variants in migraine. *J Headache Pain*. 2017;18(1):32, 10 pages.
27. Hansen EK, Olesen J. Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals. *Cephalalgia*. 2017;37(1):11-9.
28. Guo S, Vollesen AL, Hansen YB, Frandsen E, Andersen MR, Amin FM, Fahrenkrug J, Olesen J, Ashina M. Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. *Cephalalgia*. 2017;37(2):136-47.
29. Guo S, Vollesen AL, Hansen RD, Esserlind AL, Amin FM, Christensen AF, Olesen J, Ashina M. Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. *Cephalalgia*. 2017;37(2):125-35.
30. Guo S, Christensen AF, Liu ML, Janjoo BN, Olesen J, Ashina M. Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. *Cephalalgia*. 2017;37(2):114-24.

31. Ashina M, Hansen JM, BO AD, Olesen J. Human models of migraine - short-term pain for long-term gain. *Nature reviews Neurology*. 2017;13(12):713-24.
32. Arngrim N, Hougaard A, Ahmadi K, Vestergaard MB, Schytz HW, Amin FM, Larsson HBW, Olesen J, Hoffmann MB, Ashina M. Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses. *Annals of neurology*. 2017;82(6):925-39.
33. Younis S, Maarbjerg S, Reimer M, Wolfram F, Olesen J, Baron R, Bendtsen L. Quantitative sensory testing in classical trigeminal neuralgia-a blinded study in patients with and without concomitant persistent pain. *Pain*. 2016;157(7):1407-14.
34. Schytz HW, Olesen J. Laboratory tests of headache disorders - dawn of a new era? *Cephalalgia*. 2016;36(13):1268-90.
35. Padmanabhuni SS, Houssari R, Esserlind AL, Olesen J, Werge TM, Hansen TF, Bertelsen B, Tsetsos F, Paschou P, Tumer Z. Investigation of SNP rs2060546 Immediately Upstream to NTN4 in a Danish Gilles de la Tourette Syndrome Cohort. *Frontiers in neuroscience*. 2016;10:531.
36. Olesen J. From ICHD-3 beta to ICHD-3. *Cephalalgia*. 2016;36(5):401-2.
37. Olesen J. Migraine: Are migraine endophenotypes needed? *Nature reviews Neurology*. 2016;12(6):320-1.
38. Lebedeva ER, Kobzeva NR, Gilev DV, Olesen J. Factors Associated with Primary Headache According to Diagnosis, Sex, and Social Group. *Headache*. 2016;56(2):341-56.
39. Lebedeva ER, Kobzeva NR, Gilev D, Olesen J. Prevalence of primary headache disorders diagnosed according to ICHD-3 beta in three different social groups. *Cephalalgia*. 2016;36(6):579-88.
40. Hougaard Pedersen S, Maretty L, Ramachandran R, Sibbesen JA, Yakimov V, Elgaard-Christensen R, Hansen TF, Krogh A, Olesen J, Jansen-Olesen I. RNA Sequencing of Trigeminal Ganglia in *Rattus Norvegicus* after Glyceryl Trinitrate Infusion with Relevance to Migraine. *PloS one*. 2016;11(5):e0155039.
41. Hansen EK, Guo S, Ashina M, Olesen J. Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers. *Cephalalgia*. 2016;36(2):172-8.
42. Guo S, Vollesen AL, Olesen J, Ashina M. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. *Pain*. 2016;157(12):2773-81.
43. Guo S, Esserlind AL, Andersson Z, Frederiksen AL, Olesen J, Vissing J, Ashina M. Prevalence of migraine in persons with the 3243A>G mutation in mitochondrial DNA. *European journal of neurology*. 2016;23(1):175-81.
44. Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, Farh KH, Cuenca-Leon E, Muona M, Furlotte NA, Kurth T, Ingason A, McMahon G, Ligthart L, Terwindt GM, Kallela M, Freilinger TM, Ran C, Gordon SG, Stam AH, Steinberg S, Borck G, Koironen M, Quaye L, Adams HH, Lehtimäki T, Sarin AP, Wedenoja J, Hinds DA, Buring JE, Schurks M, Ridker PM, Hrafnsdóttir MG, Stefansson H, Ring SM, Hottenga JJ, Penninx BW, Farkkila M, Artto V, Kaunisto M, Vepsäläinen S, Malik R, Heath AC, Madden PA, Martin NG, Montgomery GW, Kurki MI, Kals M, Magi R, Parn K, Hamalainen E, Huang H, Byrnes AE, Franke L, Huang J, Stergiakouli E, Lee PH, Sandor C, Webber C, Cader Z, Müller-Myhsok B, Schreiber S, Meitinger T, Eriksson JG, Salomaa V, Heikkilä K, Loehrer E, Uitterlinden AG, Hofman A, van Duijn CM, Cherkas L, Pedersen LM, Stubhaug A, Nielsen CS, Mannikko M, Mihailov E, Milani L, Gobel H, Esserlind AL, Christensen AF, Hansen TF, Werge T, Kaprio J, Aromaa AJ, Raitakari O, Ikram MA, Spector T, Jarvelin MR, Metspalu A, Kubisch C, Strachan DP, Ferrari MD, Belin AC, Dichgans M, Wessman M, van den Maagdenberg AM, Zwart JA, Boomsma DI, Smith GD, Stefansson K, Eriksson N, Daly MJ, Neale BM, Olesen J, Chasman DI, Nyholt DR, Palotie A. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. *Nature genetics*. 2016;48(8):856-66.
45. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome: An electronic diary study. *Neurology*. 2016;87(3):309-13.
46. Esserlind AL, Christensen AF, Steinberg S, Grarup N, Pedersen O, Hansen T, Werge T, Hansen TF, Husemoen LL, Linneberg A, Budtz-Jørgensen E, Westergaard ML, Stefansson H, Olesen J. The

- association between candidate migraine susceptibility loci and severe migraine phenotype in a clinical sample. *Cephalalgia*. 2016;36(7):615-23.
47. Christensen SL, Petersen S, Sorensen DB, Olesen J, Jansen-Olesen I. Infusion of low dose glyceryl trinitrate has no consistent effect on burrowing behavior, running wheel activity and light sensitivity in female rats. *Journal of pharmacological and toxicological methods*. 2016;80:43-50.
  48. Christensen AF, Esserlind AL, Werge T, Stefansson H, Stefansson K, Olesen J. The influence of genetic constitution on migraine drug responses. *Cephalalgia*. 2016;36(7):624-39.
  49. Ashina S, Olesen J, Lipton RB. How Well Does the ICHD 3 (Beta) Help in Real-Life Migraine Diagnosis and Management? *Current pain and headache reports*. 2016;20(12):66, 6 pages.
  50. Arnglim N, Schytz HW, Britze J, Amin FM, Vestergaard MB, Hougaard A, Wolfram F, de Koning PJ, Olsen KS, Secher NH, Larsson HB, Olesen J, Ashina M. Migraine induced by hypoxia: an MRI spectroscopy and angiography study. *Brain*. 2016;139(Pt 3):723-37.
  51. Pedersen SH, Ramachandran R, Amrutkar DV, Petersen S, Olesen J, Jansen-Olesen I. Mechanisms of glyceryl trinitrate provoked mast cell degranulation. *Cephalalgia*. 2015;35(14):1287-97.
  52. Olesen J, Ashina M. Can nitric oxide induce migraine in normal individuals? *Cephalalgia*. 2015;35(12):1125-9.
  53. Maarbjerg S, Wolfram F, Gozalov A, Olesen J, Bendtsen L. Significance of neurovascular contact in classical trigeminal neuralgia. *Brain*. 2015;138(Pt 2):311-9.
  54. Maarbjerg S, Wolfram F, Gozalov A, Olesen J, Bendtsen L. Association between neurovascular contact and clinical characteristics in classical trigeminal neuralgia: A prospective clinical study using 3.0 Tesla MRI. *Cephalalgia*. 2015;35(12):1077-84.
  55. Maarbjerg S, Sorensen MT, Gozalov A, Bendtsen L, Olesen J. Field-testing of the ICHD-3 beta diagnostic criteria for classical trigeminal neuralgia. *Cephalalgia*. 2015;35(4):291-300.
  56. Mitsikostas DD, Ashina M, Craven A, Diener HC, Goadsby PJ, Ferrari MD, Lampl C, Paemeleire K, Pascual J, Siva A, Olesen J, Osipova V, Martelletti P. European Headache Federation consensus on technical investigation for primary headache disorders. *J Headache Pain*. 2015;17:5.
  57. Li D, Christensen AF, Olesen J. Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for migraine with aura. *Cephalalgia*. 2015;35(9):748-56.
  58. Lebedeva ER, Busygina AV, Kolotvinov VS, Sakovich VP, Olesen J. Remission of migraine after clipping of saccular intracranial aneurysms. *Acta NeurolScand*. 2015;131(2):120-6.
  59. Hougaard A, Lindberg U, Arnglim N, Larsson HB, Olesen J, Amin FM, Ashina M, Haddock BT. Evidence of a Christmas spirit network in the brain: functional MRI study. *Bmj*. 2015;351:h6266.
  60. Hansen EK, Guo S, Ashina M, Olesen J. Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers. *Cephalalgia*. 2015.
  61. Guo S, Goetze JP, Jeppesen JL, Burnett JC, Olesen J, Jansen-Olesen I, Ashina M. Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. *Peptides*. 2015;74:33-42.
  62. Esserlind AL, Christensen AF, Steinberg S, Grarup N, Pedersen O, Hansen T, Werge T, Hansen TF, Husemoen LL, Linneberg A, Budtz-Jorgensen E, Westergaard ML, Stefansson H, Olesen J. The association between candidate migraine susceptibility loci and severe migraine phenotype in a clinical sample. *Cephalalgia*. 2015.
  63. Bhatt DK, Ramachandran R, Christensen SL, Gupta S, Jansen-Olesen I, Olesen J. CGRP infusion in unanesthetized rats increases expression of c-Fos in the nucleus tractus solitarius and caudal ventrolateral medulla, but not in the trigeminal nucleus caudalis. *Cephalalgia*. 2015;35(3):220-33.
  64. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. *Cephalalgia*. 2014;34(6):409-25.
  65. Schytz HW, Ashina M, Magyar M, Larsen VA, Olesen J, Iversen HK. Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta. *Cephalalgia*. 2014;34(9):712-6.

66. Ramachandran R, Bhatt DK, Ploug KB, Hay-Schmidt A, Jansen-Olesen I, Gupta S, Olesen J. Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation. *Cephalalgia*. 2014;34(2):136-47.
67. Olesen J. Problem areas in the International Classification of Headache Disorders, 3rd edition (beta). *Cephalalgia*. 2014;34(14):1193-9.
68. Olesen J. Highlights in headache research in 2013. *Lancet Neurol*. 2014;13(1):5-7.
69. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. *Headache*. 2014;54(10):1574-82.
70. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Concomitant persistent pain in classical trigeminal neuralgia--evidence for different subtypes. *Headache*. 2014;54(7):1173-83.
71. Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christophersen DV, Olesen J. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. *Neuropeptides*. 2014;48(2):53-64.
72. Hougaard A, Amin FM, Hoffmann MB, Rostrup E, Larsson HB, Asghar MS, Larsen VA, Olesen J, Ashina M. Interhemispheric differences of fMRI responses to visual stimuli in patients with side-fixed migraine aura. *HumBrain Mapp*. 2014;35(6):2714-23.
73. Guo S, Olesen J, Ashina M. Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. *Brain*. 2014;137(Pt 11):2951-9.
74. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. *Lancet Neurol*. 2014;13(11):1100-7.
75. DiLuca M, Olesen J. The cost of brain diseases: a burden or a challenge? *Neuron*. 2014;82(6):1205-8.
76. Bhatt DK, Gupta S, Ploug KB, Jansen-Olesen I, Olesen J. mRNA distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. *NeurosciLett*. 2014;559:99-104.
77. Bhatt DK, Gupta S, Olesen J, Jansen-Olesen I. PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells. *Cephalalgia*. 2014;34(11):877-86.
78. Arnglim N, Schytz HW, Hauge MK, Ashina M, Olesen J. Carbon monoxide may be an important molecule in migraine and other headaches. *Cephalalgia*. 2014;34(14):1169-80.
79. Arnglim N, Schytz HW, Asghar MS, Amin FM, Hougaard A, Larsen VA, de Koning PJ, Larsson HB, Olesen J, Ashina M. Association of acetazolamide infusion with headache and cranial artery dilation in healthy volunteers. *Pain*. 2014;155(8):1649-58.
80. Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J, Ashina M. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. *Brain*. 2014;137(Pt 3):779-94.
81. Olesen J. ICHD-3 beta is published. Use it immediately. *Cephalalgia*. 2013;33(9):627-8.
82. Olesen J. Ten-year anniversary of the European Brain Council: the major achievements. *EurJNeurol*. 2013;20(4):595-6.
83. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, Bisdorff A, Versino M, Evers S, Newman-Toker D. [Vestibular migraine: diagnostic criteria: consensus document of the Barany Society and the International Headache Society]. *Nervenarzt*. 2013;84(4):511-6.
84. Lebedeva ER, Olesen J, Osipova VV, Volkova LI, Tabeeva GR, Steiner TJ. The Yekaterinburg headache initiative: an interventional project, within the Global Campaign against Headache, to reduce the burden of headache in Russia. *JHeadache Pain*. 2013;14:101.

85. Lebedeva ER, Gurary NM, Sakovich VP, Olesen J. Migraine before rupture of intracranial aneurysms. *JHeadache Pain*. 2013;14:15.
86. Jansen-Olesen I, Tfelt-Hansen P, Olesen J. Animal migraine models for drug development: status and future perspectives. *CNSDrugs*. 2013;27(12):1049-68.
87. Hougaard A, Amin FM, Hoffmann MB, Rostrup E, Larsson HB, Asghar MS, Larsen VA, Olesen J, Ashina M. Interhemispheric differences of fMRI responses to visual stimuli in patients with side-fixed migraine aura. *HumBrain Mapp*. 2013.
88. Hougaard A, Amin FM, Hauge AW, Ashina M, Olesen J. Provocation of migraine with aura using natural trigger factors. *Neurology*. 2013;80(5):428-31.
89. Henriksen OM, Kruuse C, Olesen J, Jensen LT, Larsson HB, Birk S, Hansen JM, Wienecke T, Rostrup E. Sources of variability of resting cerebral blood flow in healthy subjects: a study using (1)(3)(3)Xe SPECT measurements. *JCerebBlood Flow Metab*. 2013;33(5):787-92.
90. Headache Classification Committee of the International Headache S. The International Classification of Headache Disorder. *Cephalalgia*. 2013;33(9):629-80.
91. Guo S, Ashina M, Olesen J, Birk S. The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. *Cephalalgia*. 2013;33(5):301-7.
92. Esserlind AL, Christensen AF, Le H, Kirchmann M, Hauge AW, Toyserkani NM, Hansen T, Grarup N, Werge T, Steinberg S, Bettella F, Stefansson H, Olesen J. Replication and meta-analysis of common variants identifies a genome-wide significant locus in migraine. *EurJNeurol*. 2013;20(5):765-72.
93. Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, Olesen J. NXN-188, a selective nNOS inhibitor and a 5-HT<sub>1B/1D</sub> receptor agonist, inhibits CGRP release in preclinical migraine models. *Cephalalgia*. 2013;33(2):87-100.
94. Ashina M, Hansen JM, Olesen J. Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. *Cephalalgia*. 2013;33(8):540-53.
95. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: update. *CurrOpinNeurol*. 2013;26(3):269-75.
96. Amin FM, Asghar MS, Ravneberg JW, de Koning PJ, Larsson HB, Olesen J, Ashina M. The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers. *Cephalalgia*. 2013;33(12):1009-16.
97. Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, Larsson HB, Olesen J, Ashina M. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. *Lancet Neurol*. 2013;12(5):454-61.
98. Tfelt-Hansen PC, Olesen J. The 5-HT<sub>1F</sub> receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. *JHeadache Pain*. 2012;13(4):271-5.
99. Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. *CNSDrugs*. 2012;26(5):375-82.
100. Rudkjobing LA, Esserlind AL, Olesen J. Future possibilities in migraine genetics. *J Headache Pain*. 2012;13(7):505-11.
101. Ramachandran R, Bhatt DK, Ploug KB, Olesen J, Jansen-Olesen I, Hay-Schmidt A, Gupta S. A naturalistic glyceryl trinitrate infusion migraine model in the rat. *Cephalalgia*. 2012;32(1):73-84.
102. Ploug KB, Amrutkar DV, Baun M, Ramachandran R, Iversen A, Lund TM, Gupta S, Hay-Schmidt A, Olesen J, Jansen-Olesen I. K(ATP) channel openers in the trigeminovascular system. *Cephalalgia*. 2012;32(1):55-65.
103. Olesen J, Jansen-Olesen I. Towards a reliable animal model of migraine. *Cephalalgia*. 2012;32(7):578-80.
104. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. *EurJNeurol*. 2012;19(1):155-62.
105. Olesen J. Ten-year anniversary of the European Brain Council: The major achievements. *EurJNeurol*. 2012.

106. Olesen J. Detoxification for medication overuse headache is the primary task. *Cephalalgia*. 2012;32(5):420-2.
107. Myren M, Olesen J, Gupta S. Prostaglandin E2 receptor expression in the rat trigeminal-vascular system and other brain structures involved in pain. *NeurosciLett*. 2012;506(1):64-9.
108. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, Bisdorff A, Versino M, Evers S, Newman-Toker D. Vestibular migraine: diagnostic criteria. *J VestibRes*. 2012;22(4):167-72.
109. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J. Increase in self-reported migraine prevalence in the Danish adult population: a prospective longitudinal population-based study. *BMJ Open*. 2012;2(4).
110. Esserlind AL, Kirchmann M, Hauge AW, Le H, Olesen J. A genotype-phenotype analysis of the 8q22.1 variant in migraine with aura. *EurJNeurol*. 2012;19(4):603-9.
111. Christensen AF, Le H, Kirchmann M, Olesen J. Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1. *JHeadache Pain*. 2012;13(1):21-7.
112. Baun M, Pedersen MH, Olesen J, Jansen-Olesen I. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. *Cephalalgia*. 2012;32(4):337-45.
113. Asghar MS, Hansen AE, Larsson HB, Olesen J, Ashina M. Effect of CGRP and sumatriptan on the BOLD response in visual cortex. *JHeadache Pain*. 2012;13(2):159-66.
114. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. *Cephalalgia*. 2012;32(11):822-33.
115. Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. *Pain*. 2012;153(4):830-8.
116. Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJH, Larsson HBW, Olesen J, Ashina M. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. *Cephalalgia*. 2012;32(2):140-9.
117. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van OJ, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. *EurNeuropsychopharmacol*. 2011;21(9):655-79.
118. Wienecke T, Olesen J, Ashina M. Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D(2) (PGD(2)). *Cephalalgia*. 2011;31(1):65-76.
119. Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. *Cephalalgia*. 2011;31(6):748-50.
120. Poulsen AN, Jansen-Olesen I, Olesen J, Klaerke DA. Neuronal fast activating and meningeal silent modulatory BK channel splice variants cloned from rat. *Pflugers Arch*. 2011;461(1):65-75.
121. Olesen J, Ashina M. Emerging migraine treatments and drug targets. *Trends PharmacolSci*. 2011;32(6):352-9.
122. Olesen J. New plans for headache classification: ICHD-3. *Cephalalgia*. 2011;31(1):4-5.
123. Myren M, Olesen J, Gupta S. Pharmacological and expression profile of the prostaglandin I(2) receptor in the rat craniovascular system. *VasculPharmacol*. 2011;55(1-3):50-8.
124. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J. Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. *JHeadache Pain*. 2011;12(2):157-72.
125. Le H, Tfelt-Hansen P, Russell MB, Skytthe A, Kyvik KO, Olesen J. Co-morbidity of migraine with somatic disease in a large population-based study. *Cephalalgia*. 2011;31(1):43-64.
126. Jensen R, Tassorelli C, Rossi P, Allena M, Osipova V, Steiner T, Sandrini G, Olesen J, Nappi G. A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. a multicentre European and Latin American study. *Cephalalgia*. 2011;31(15):1549-60.
127. Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient's historical triptan response. *Headache*. 2011;51(1):64-72.

128. Hauge AW, Kirchmann M, Olesen J. Characterization of consistent triggers of migraine with aura. *Cephalalgia*. 2011;31(4):416-38.
129. Hansen JM, Thomsen LL, Olesen J, Ashina M. Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. *Headache*. 2011;51(4):544-53.
130. Hansen JM, Hauge AW, Ashina M, Olesen J. Trigger factors for familial hemiplegic migraine. *Cephalalgia*. 2011;31(12):1274-81.
131. Hansen JM, Bolla M, Magis D, de PV, Ashina M, Thomsen LL, Olesen J, Schoenen J. Habituation of evoked responses is greater in patients with familial hemiplegic migraine than in controls: a contrast with the common forms of migraine. *EurJNeurol*. 2011;18(3):478-85.
132. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, den Bergh PV, van OJ, Vos P, Xu W, Wittchen HU, Jonsson B, Olesen J. Cost of disorders of the brain in Europe 2010. *EurNeuropsychopharmacol*. 2011;21(10):718-79.
133. Geller F, Feenstra B, Zhang H, Shaffer JR, Hansen T, Esserlind AL, Boyd HA, Nohr EA, Timpson NJ, Fatemifar G, Paternoster L, Evans DM, Weyant RJ, Levy SM, Lathrop M, Smith GD, Murray JC, Olesen J, Werge T, Marazita ML, Sorensen TI, Melbye M. Genome-wide association study identifies four loci associated with eruption of permanent teeth. *PLoSGenet*. 2011;7(9):e1002275.
134. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine--classification, characteristics and treatment. *NatRevNeurol*. 2011;8(3):162-71.
135. Di LM, Baker M, Corradetti R, Kettenmann H, Mendlewicz J, Olesen J, Ragan I, Westphal M. Consensus document on European brain research. *EurJNeurosci*. 2011;33(5):768-818.
136. Chan KY, Baun M, de VR, van den Bogaerdt AJ, Dirven CM, Danser AH, Jansen-Olesen I, Olesen J, Villalon CM, MaassenVanDenBrink A, Gupta S. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. *Cephalalgia*. 2011;31(2):181-9.
137. Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. *EurJPharmacol*. 2011;670(1):186-94.
138. Ashina M, Tfelt-Hansen P, Dalgaard P, Olesen J. Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. *Cephalalgia*. 2011;31(6):683-90.
139. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB, Olesen J, Ashina M. Evidence for a vascular factor in migraine. *AnnNeurol*. 2011;69(4):635-45.
140. Antonova M, Wienecke T, Olesen J, Ashina M. Pro-inflammatory and vasoconstricting prostanoid PGF(2 alpha) causes no headache in man. *Cephalalgia*. 2011;31(15):1532-41.
141. Antonova M, Wienecke T, Maubach K, Thomas E, Olesen J, Ashina M. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E-2 human model of headache. *Journal of Headache and Pain*. 2011;12(5):551-9.
142. Wulf-Johansson H, Amrutkar DV, Hay-Schmidt A, Poulsen AN, Klaerke DA, Olesen J, Jansen-Olesen I. Localization of large conductance calcium-activated potassium channels and their effect on calcitonin gene-related peptide release in the rat trigemino-neuronal pathway. *Neuroscience*. 2010;167(4):1091-102.
143. Wienecke T, Olesen J, Ashina M. Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. *Cephalalgia*. 2010;30(2):179-90.
144. Tvedskov JF, Tfelt-Hansen P, Petersen KA, Jensen LT, Olesen J. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. *Cephalalgia*. 2010;30(11):1346-53.
145. Tvedskov JF, Iversen HK, Olesen J, Tfelt-Hansen P. Nitroglycerin provocation in normal subjects is not a useful human migraine model? *Cephalalgia*. 2010;30(8):928-32.

146. Steiner TJ, Olesen J. Implementing the International Classification of Headache Disorders, 2nd edition (ICHD-II). *HandbClinNeurol*. 2010;97:147-59.
147. Schytz HW, Wienecke T, Olesen J, Ashina M. Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. *Cephalalgia*. 2010;30(3):337-45.
148. Schytz HW, Olesen J, Ashina M. The PACAP receptor: a novel target for migraine treatment. *Neurotherapeutics*. 2010;7(2):191-6.
149. Schytz HW, Holst H, Arendt-Nielsen L, Olesen J, Ashina M. Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. *JHeadache Pain*. 2010;11(4):309-16.
150. Ramachandran R, Ploug KB, Hay-Schmidt A, Olesen J, Jansen-Olesen I, Gupta S. Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats. *NeurosciLett*. 2010;484(3):192-6.
151. Ploug KB, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I. Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. *EurJPharmacol*. 2010;637(1-3):109-17.
152. Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. *Lancet*. 2010;376(9755):1825-6.
153. Olesen J. 5-Hydroxytryptamine 1F (5-HT<sub>1F</sub>) receptor agonism. A possible new treatment principle for acute migraine attacks. *Cephalalgia*. 2010;30(10):1157-8.
154. Olesen J. Migraine: A neural pathway for photophobia in migraine. *NatRevNeurol*. 2010;6(5):241-2.
155. Olesen J. Nitric oxide-related drug targets in headache. *Neurotherapeutics*. 2010;7(2):183-90.
156. Myren M, Baun M, Ploug KB, Jansen-Olesen I, Olesen J, Gupta S. Functional and molecular characterization of prostaglandin E<sub>2</sub> dilatory receptors in the rat craniovascular system in relevance to migraine. *Cephalalgia*. 2010;30(9):1110-22.
157. Kruuse C, Iversen HK, Jansen-Olesen I, Edvinsson L, Olesen J. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. *Cephalalgia*. 2010;30(4):467-74.
158. Jensen R, Zeeberg P, Dehlendorff C, Olesen J. Predictors of outcome of the treatment programme in a multidisciplinary headache centre. *Cephalalgia*. 2010;30(10):1214-24.
159. Hauge AW, Kirchmann M, Olesen J. Trigger factors in migraine with aura. *Cephalalgia*. 2010;30(3):346-53.
160. Hauge AW, Hougaard A, Olesen J. On the methodology of drug trials in migraine with aura. *Cephalalgia*. 2010;30(9):1041-8.
161. Hansen JM, Thomsen LL, Olesen J, Ashina M. Coexisting typical migraine in familial hemiplegic migraine. *Neurology*. 2010;74(7):594-600.
162. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. *Cephalalgia*. 2010;30(10):1179-86.
163. Gupta S, Bhatt DK, Boni LJ, Olesen J. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. *Cephalalgia*. 2010;30(1):27-36.
164. Gupta S, Amrutkar DV, Mataji A, Salmasi H, Hay-Schmidt A, Sheykhzade M, Messlinger K, Olesen J, Jansen-Olesen I. Evidence for CGRP re-uptake in rat dura mater encephali. *BrJPharmacol*. 2010;161(8):1885-98.
165. Daugaard D, Tfelt-Hansen P, Thomsen LL, Iversen HK, Olesen J. No effect of pure oxygen inhalation on headache induced by glyceryl trinitrate. *JHeadache Pain*. 2010;11(2):93-5.
166. Bhatt DK, Ploug KB, Ramachandran R, Olesen J, Gupta S. Activation of PAR-2 elicits NO-dependent and CGRP-independent dilation of the dural artery. *Headache*. 2010;50(6):1017-30.
167. Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J. Matrix metalloproteinases during and outside of migraine attacks without aura. *Cephalalgia*. 2010;30(3):303-10.
168. Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, van der Koning P, Larsson HB, Olesen J, Ashina M. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. *Neurology*. 2010;75(17):1520-6.

169. Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, Nyholt DR, Dimas AS, Freilinger T, Muller-Myhsok B, Artto V, Inouye M, Alakurtti K, Kaunisto MA, Hamalainen E, de VB, Stam AH, Weller CM, Heinze A, Heinze-Kuhn K, Goebel I, Borck G, Gobel H, Steinberg S, Wolf C, Bjornsson A, Gudmundsson G, Kirchmann M, Hauge A, Werge T, Schoenen J, Eriksson JG, Hagen K, Stovner L, Wichmann HE, Meitinger T, Alexander M, Moebus S, Schreiber S, Aulchenko YS, Breteler MM, Uitterlinden AG, Hofman A, van Duijn CM, Tikka-Kleemola P, Vepsalainen S, Lucae S, Tozzi F, Muglia P, Barrett J, Kaprio J, Farkkila M, Peltonen L, Stefansson K, Zwart JA, Ferrari MD, Olesen J, Daly M, Wessman M, van den Maagdenberg AM, Dichgans M, Kubisch C, Dermitzakis ET, Frants RR, Palotie A. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. *NatGenet.* 2010;42(10):869-73.
170. Zeeberg P, Olesen J, Jensen R. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria. *Cephalalgia.* 2009;29(2):214-20.
171. Wulf-Johansson H, Hay-Schmidt A, Poulsen AN, Klaerke DA, Olesen J, Jansen-Olesen I. Expression of BK(Ca) channels and the modulatory beta-subunits in the rat and porcine trigeminal ganglion. *Brain Res.* 2009.
172. Wulf H, Hay-Schmidt A, Poulsen AN, Klaerke DA, Olesen J, Jansen-Olesen I. Molecular investigations of BK(Ca) channels and the modulatory beta-subunits in porcine basilar and middle cerebral arteries. *J MolHistol.* 2009;40(2):87-97.
173. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2(PGE2) induces headache in healthy subjects. *Cephalalgia.* 2009;29(5):509-19.
174. Wienecke T, Olesen J, Ashina M. Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs. *Cephalalgia.* 2009.
175. Villalon CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. *PharmacolTher.* 2009;124(3):309-23.
176. Tfelt-Hansen P, Olesen J. LETTER TO THE EDITOR. *Cephalalgia.* 2009.
177. Tfelt-Hansen P, Daugaard D, Lassen LH, Iversen HK, Olesen J. Prednisolone reduces nitric oxide-induced migraine. *EurJ Neurol.* 2009.
178. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeny LA, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de FR, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Touloupoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St CD, Goldstein DB, Stefansson K, Collier DA. Common variants conferring risk of schizophrenia. *Nature.* 2009;460(7256):744-7.
179. Schytz HW, Wienecke T, Oturai PS, Olesen J, Ashina M. The cholinomimetic agent carbachol induces headache in healthy subjects. *Cephalalgia.* 2009;29(2):258-68.
180. Schytz HW, Wienecke T, Olesen J, Ashina M. Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. *Cephalalgia.* 2009.
181. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. *Brain.* 2009;132(Pt 1):16-25.
182. Poulsen AN, Wulf H, Hay-Schmidt A, Jansen-Olesen I, Olesen J, Klaerke DA. Differential expression of BK channel isoforms and beta-subunits in rat neuro-vascular tissues. *BiochimBiophysActa.* 2009;1788(2):380-9.
183. Petersen KA, Birk S, Kitamura K, Olesen J. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. *Cephalalgia.* 2009;29(1):23-30.

184. Olesen J, Tfelt-Hansen P, Ashina M. Finding new drug targets for the treatment of migraine attacks. *Cephalalgia*. 2009;29(9):909-20.
185. Olesen J, Steiner T, Bousser MG, Diener HC, Dodick D, First MB, Goadsby PJ, Gobel H, Lainez MJ, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD. Proposals for new standardized general diagnostic criteria for the secondary headaches. *Cephalalgia*. 2009.
186. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. *Lancet Neurol*. 2009;8(7):679-90.
187. Olesen J. Dedicated chairs in headache science: the way forward? *Cephalalgia*. 2009;29(1):1-2.
188. Olesen J. The future of headache classification and classification research. *Cephalalgia*. 2009.
189. Lindholt M, Petersen KA, Tvedskov JF, Iversen HK, Olesen J, Tfelt-Hansen P. Lack of effect of norepinephrine on cranial haemodynamics and headache in healthy volunteers. *Cephalalgia*. 2009;29(3):384-7.
190. Kruuse C, Iversen HK, Jansen-Olesen I, Edvinsson L, Olesen J. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. *Cephalalgia*. 2009.
191. Kruse LS, Moller M, Tibaek M, Gammeltoft S, Olesen J, Kruuse C. PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system. *Brain Res*. 2009;1281:25-34.
192. Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. *Lancet Neurol*. 2009;8(8):718-23.
193. Hauge A, Kirchmann M, Olesen J. Trigger factors in migraine with aura. *Cephalalgia*. 2009.
194. Gupta S, Bhatt DK, Boni LJ, Olesen J. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. *Cephalalgia*. 2009.
195. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. *Cephalalgia*. 2009;29(7):742-50.
196. Daugaard D, Thomsen LL, Iversen HK, Olesen J. Delayed migraine-like headache in healthy volunteers after a combination of acetazolamide and glyceryl trinitrate. *Cephalalgia*. 2009.
197. Dahlof CG, Hauge AW, Olesen J. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. *Cephalalgia*. 2009;29 Suppl 2:7-16.
198. Boni LJ, Ploug KB, Olesen J, Jansen-Olesen I, Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. *Cephalalgia*. 2009;29(8):837-47.
199. Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J. Matrix metalloproteinases during and outside of migraine attacks without aura. *Cephalalgia*. 2009.
200. Wulf H, Hay-Schmidt A, Poulsen AN, Klaerke DA, Olesen J, Jansen-Olesen I. Molecular studies of BKCa channels in intracranial arteries: presence and localization. *Cell Tissue Res*. 2008;334(3):359-69.
201. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostacyclin (epoprostenol) induces headache in healthy subjects. *Pain*. 2008;139(1):106-16.
202. Thomsen LL, Oestergaard E, Bjornsson A, Stefansson H, Fasquel AC, Gulcher J, Stefansson K, Olesen J. Screen for CACNA1A and ATP1A2 mutations in sporadic hemiplegic migraine patients. *Cephalalgia*. 2008;28(9):914-21.
203. Tfelt-Hansen P, Thorbjorn JL, Olesen J. Delayed hyperperfusion following migraine with a prolonged aphasic aura in a patient with CADASIL. *Cephalalgia*. 2008;28(8):899-902.
204. Tfelt-Hansen P, Jensen LT, Olesen J. Delayed hyperperfusion following migraine with a prolonged aphasic aura in a patient with CADASIL. *Cephalalgia*. 2008;28(8):899-902.
205. Tfelt-Hansen P, Ashina M, Olesen J. [Clinical symptoms and pathophysiology of migraine]. *Ugeskrift for laeger*. 2008;170(41):3231-4.

206. Tassorelli C, Sances G, Allena M, Ghiotto N, Bendtsen L, Olesen J, Nappi G, Jensen R. The usefulness and applicability of a basic headache diary before first consultation: results of a pilot study conducted in two centres. *Cephalalgia*. 2008;28(10):1023-30.
207. Stefansson H, Rujescu D, Cichon S, Pietilainen OPH, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, Shianna KV, Ge DL, Need AC, Crombie C, Fraser G, Walker N, Lonqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Touloupoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemenev LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nothen MM, Peltonen L, Collier DA, St Clair D, Stefansson K. Large recurrent microdeletions associated with schizophrenia. *Nature*. 2008;455(7210):232-U61.
208. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Touloupoulou T, Bramon E, Di FM, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemenev LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nothen MM, Peltonen L, Collier DA, St CD, Stefansson K. Large recurrent microdeletions associated with schizophrenia. *Nature*. 2008;455(7210):232-6.
209. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. *Cephalalgia*. 2008;28(3):226-36.
210. Ploug KB, Sorensen MA, Strobeck L, Klaerke DA, Hay-Schmidt A, Sheykhzade M, Olesen J, Jansen-Olesen I. K ATP channels in pig and human intracranial arteries. *EurJ Pharmacol*. 2008;601(1-3):43-9.
211. Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I. K-ATP channel expression and pharmacological in vivo and in vitro studies of the K-ATP channel blocker PNU-37883A in rat middle meningeal arteries. *Br J Pharmacol*. 2008;154(1):72-81.
212. Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I. K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries. *BrJ Pharmacol*. 2008;154(1):72-81.
213. Olesen J, Sobscki P, Truelsen T, Sestoft D, Jonsson B. Cost of disorders of the brain in Denmark. *NordJ Psychiatry*. 2008;62(2):114-20.
214. Olesen J, Sobocki P, Truelsen T, Sestoft DM, Jonsson B. Cost of disorders of the brain in Denmark. *Nordic Journal of Psychiatry*. 2008;62(2):114-20.
215. Olesen J. The International Classification of Headache Disorders. *Headache*. 2008;48(5):691-3.
216. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. *Pharmacol Ther*. 2008;120(2):157-71.
217. Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. *J Headache Pain*. 2008;9(3):151-7.
218. Hansen JM, Thomsen LL, Olesen J, Ashina M. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. *Cephalalgia*. 2008;28(5):496-505.

219. Hansen JM, Thomsen LL, Olesen J, Ashina M. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. *Neurology*. 2008;71(11):841-7.
220. Hansen JM, Thomsen LL, Marconi R, Casari G, Olesen J, Ashina M. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. *Cephalalgia*. 2008;28(4):367-75.
221. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J. Role of K ATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. *Headache*. 2008;48(8):1202-13.
222. Christiansen I, Iversen HK, Olesen J, Tfelt-Hansen P. Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. *J Headache Pain*. 2008;9(4):215-20.
223. Thomsen LL, Kirchmann M, Bjornsson A, Stefansson H, Jensen RM, Fasquel AC, Petursson H, Stefansson M, Frigge ML, Kong A, Gulcher J, Stefansson K, Olesen J. The genetic spectrum of a population-based sample of familial hemiplegic migraine. *Brain*. 2007;130:346-56.
224. Sobocki P, Olesen J, Jonsson B. Brain research has high returns but Europe is lagging behind. *European Journal of Neurology*. 2007;14(6):708-10.
225. Olesen J, Lekander I, Sobocki P. Resource allocation to brain research in Denmark: an example for other European countries. *European Journal of Neurology*. 2007;14(6):667-71.
226. Olesen J, Lekander I, Andlin-Sobocki P, Jonsson B. Funding of headache research in Europe. *Cephalalgia*. 2007;27(9):995-9.
227. Olesen J. Collaboration to promote neurological research--the European Brain Council experience. *NatClinPractNeurol*. 2007;3(6):298-9.
228. Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I. Effect of two novel CGRP-binding compounds in a closed cranial window rat model. *European Journal of Pharmacology*. 2007;567(1-2):117-24.
229. Hansen JM, Pedersen DL, Larsen VA, Sanchez-del-Rio M, Linera JRA, Olesen J, Ashina M. Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers. *Cephalalgia*. 2007;27(2):118-27.
230. Hansen JM, Pedersen D, Larsen VA, Sanchez-del-Rio M, Alvarez Linera JR, Olesen J, Ashina M. Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers. *Cephalalgia*. 2007;27(2):118-27.
231. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J. Role of BKCa channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat. *Cephalalgia*. 2007;27(10):1120-7.
232. Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. *Regulatory Peptides*. 2007;140(3):185-91.
233. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. *Neurology*. 2006;66(12):1894-8.
234. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. *Cephalalgia*. 2006;26(10):1192-8.
235. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache - The effect of a 2-month drug-free period. *Neurology*. 2006;66(12):1894-8.
236. Tfelt-Hansen P, Olesen J. Increasing the effect of triptans in migraine. *Lancet*. 2006;368(9544):1313-4.
237. Sobocki P, Lekander I, Berwick S, Olesen J, Jonsson B. Resource allocation to brain research in Europe (RABRE). *European Journal of Neuroscience*. 2006;24(10):2691-3.
238. Ramadan NM, Olesen J. Classification of headache disorders. *Seminars in Neurology*. 2006;26(2):157-62.
239. Ploug KB, Edvinsson L, Olesen J, Jansen-Olesen I. Pharmacological and molecular comparison of K(ATP) channels in rat basilar and middle cerebral arteries. *EurJPharmacol*. 2006;553(1-3):254-62.

240. Ploug KB, Edvinsson L, Olesen J, Jansen-Olesen I. Pharmacological and molecular comparison of K-ATP channels in rat basilar and middle cerebral arteries. *European Journal of Pharmacology*. 2006;553(1-3):254-62.
241. Olesen J, Freund TF. European Brain Council: partnership to promote European and national brain research. *Trends in Neurosciences*. 2006;29(9):493-5.
242. Olesen J, Boussier MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia*. 2006;26(6):742-6.
243. Olesen J, Boussier MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia*. 2006;26(6):742-6.
244. Olesen J, Baker MG, Freund T, di Luca M, Mendlewicz J, Ragan I, Westphal M. Consensus document on European brain research. *Journal of Neurology Neurosurgery and Psychiatry*. 2006;77:1-49.
245. Olesen J, Baker MG, Freund T, Di LM, Mendlewicz J, Ragan I, Westphal M. Consensus document on European brain research. *J Neurol Neurosurg Psychiatry*. 2006;77 Suppl 1:i1-49.
246. Olesen J. International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. *Cephalalgia*. 2006;26(12):1409-10.
247. Olesen J. A view of EBC Consensus Document on Brain Research in Europe. *European Journal of Neurology*. 2006;13:309-.
248. Olesen J. Are headache disorders caused by neurobiological mechanisms? *Current Opinion in Neurology*. 2006;19(3):277-80.
249. Nappi G, Jensen R, Nappi RE, Sances G, Torelli P, Olesen J. Diaries and calendars for migraine. A review. *Cephalalgia*. 2006;26(8):905-16.
250. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J. Dipyridamole may induce migraine in patients with migraine without aura. *Cephalalgia*. 2006;26(8):925-33.
251. Kruse LS, Sandholdt NTH, Gammeltoft S, Olesen J, Kruuse C. Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system. *Neuroscience Letters*. 2006;404(1-2):202-7.
252. Kirchmann M, Thomsen LL, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. *Neurology*. 2006;66(6):880-6.
253. Kirchmann M, Seven E, Bjornsson A, Bjornssdottir G, Gulcher JR, Stefansson K, Olesen J. Validation of the deCODE Migraine Questionnaire (DMQ3) for use in genetic studies. *European Journal of Neurology*. 2006;13(11):1239-44.
254. Juhl L, Petersen KA, Larsen EH, Jansen-Olesen I, Olesen J. The in vivo effect of adrenomedullin on rat dural and pial arteries. *European Journal of Pharmacology*. 2006;538(1-3):101-7.
255. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. *Cephalalgia*. 2006;26(8):992-1003.
256. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? *Cephalalgia*. 2006;26(7):769-71.
257. Eriksen MK, Thomsen LL, Olesen J. Implications of clinical subtypes of migraine with aura. *Headache*. 2006;46(2):286-97.
258. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. *Cephalalgia*. 2006;26(11):1304-9.
259. Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. *Cephalalgia*. 2005;25(12):1159-67.
260. Wittchen HU, Jonsson B, Olesen J. Towards a better understanding of the size and burden and cost of brain disorders in Europe. *European Neuropsychopharmacology*. 2005;15(4):355-6.
261. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. *Annals of Neurology*. 2005;58(4):561-8.

262. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ. The International Classification of Headache Disorders, 2nd Edition (ICHD-II) - revision of criteria for 8.2 Medication-overuse headache. *Cephalalgia*. 2005;25(6):460-5.
263. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache. *Cephalalgia*. 2005;25(6):460-5.
264. Petersen KA, Nilsson E, Olesen J, Edvinsson L. Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. *Cephalalgia*. 2005;25(6):424-32.
265. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. *Clinical Pharmacology & Therapeutics*. 2005;77(3):202-13.
266. Petersen KA, Dyrby L, Williamson D, Edvinsson L, Olesen J. Effect of hypotension and carbon dioxide changes in an improved genuine closed cranial window rat model. *Cephalalgia*. 2005;25(1):23-9.
267. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. *Cephalalgia*. 2005;25(2):139-47.
268. Olesen J. The international classification of headache disorders, 2(nd) edition: Application to practice. *Functional Neurology*. 2005;20(2):61-8.
269. Lassen LH, Sperling B, Andersen AR, Olesen J. The effect of i.v. L-N-G methylarginine hydrochloride (L-NMMA : 546C88) on basal and acetazolamide (Diamox ((R))) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man. *Cephalalgia*. 2005;25(5):344-52.
270. Kruuse C, Khurana TS, Rybalkin SD, Birk S, Engel U, Edvinsson L, Olesen J. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. *European Journal of Pharmacology*. 2005;521(1-3):105-14.
271. Juhl L, Petersen KA, Larsen EH, Olesen J. The effect of antagonists on adrenomedullin-induced vasodilation of dural and pial arteries studied in the genuine closed cranial window model. *Cephalalgia*. 2005;25(10):871-2.
272. Gozalov A, Petersen KA, Mortensen C, Jansen-Olesen I, Klaerke D, Olesen J. Role of KATP channels in the regulation of rat dura and pia artery diameter. *Cephalalgia*. 2005;25(4):249-60.
273. Gozalov A, Petersen KA, Mortensen C, Jansen-Olesen I, Klaerke D, Olesen J. Role of K-ATP channels in the regulation of rat dura and pia artery diameter. *Cephalalgia*. 2005;25(4):249-60.
274. Eriksen MK, Thomsen LL, Olesen J. The visual aura rating scale (VARs) for migraine aura diagnosis. *Cephalalgia*. 2005;25(10):801-10.
275. Eriksen MK, Thomsen LL, Olesen J. Sensitivity and specificity of the new international diagnostic criteria for migraine with aura. *Journal of Neurology Neurosurgery and Psychiatry*. 2005;76(2):212-7.
276. Dodel R, Andlin-Sobocki P, Beghi E, Berg J, Jonsson L, Ekman M, Forsgren L, Jonsson B, Kobelt G, Lindgren P, Olesen J, Westphal M, Wittchen HU. European Brain Council: Epidemiology of brain diseases in Europe. *European Journal of Neurology*. 2005;12:8-.
277. Birk S, Petersen KA, Kruuse C, Guieu R, Jonassen O, Eisert W, Olesen J. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. *Cephalalgia*. 2005;25(5):369-77.
278. Ashina M, Jorgensen M, Stallknecht B, Mork H, Bendtsen L, Pedersen JF, Olesen J, Jensen R. No release of interstitial glutamate in experimental human model of muscle pain. *European Journal of Pain*. 2005;9(3):337-43.
279. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. *European Journal of Neurology*. 2005;12:1-92.

280. Ulrich V, Gervil M, Olesen J. The relative influence of environment and genes in episodic tension-type headache. *Neurology*. 2004;62(11):2065-9.
281. Tvedskov JF, Thomsen LL, Thomsen LL, Iversen HK, Williams P, Gibson A, Jenkins K, Peck R, Olesen J. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. *Cephalalgia*. 2004;24(12):1076-87.
282. Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Williams P, Olesen J. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. *Cephalalgia*. 2004;24(7):576-85.
283. Tvedskov JF, Iversen HK, Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. *Cephalalgia*. 2004;24(10):875-82.
284. Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. *Cephalalgia*. 2004;24(1):29-36.
285. Thomsen LL, Olesen J. Sporadic hemiplegic migraine. *Cephalalgia*. 2004;24(12):1016-23.
286. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. *Br J Pharmacol*. 2004;143(6):697-704.
287. Olesen J, Steiner TJ. The international classification of headache disorders, 2nd edn (ICDH-II). *Journal of Neurology Neurosurgery and Psychiatry*. 2004;75(6):808-11.
288. Olesen J, Lipton RB. Headache classification update 2004. *Current Opinion in Neurology*. 2004;17(3):275-82.
289. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. *European Journal of Neurology*. 2004;11(10):671-7.
290. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *NEnglJMed*. 2004;350(11):1104-10.
291. Mork H, Ashina M, Bendtsen L, Olesen J, Jensen R. Possible mechanisms of pain perception in patients with episodic tension-type headache. A new experimental model of myofascial pain. *Cephalalgia*. 2004;24(6):466-75.
292. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. *Neurology*. 2004;63(3):427-35.
293. Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J. Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. *Cephalalgia*. 2004;24(7):547-53.
294. Eriksen MK, Thomsen LL, Olesen J. New international classification of migraine with aura (ICHD-2) applied to 362 migraine patients. *European Journal of Neurology*. 2004;11(9):583-91.
295. Eriksen MK, Thomsen LL, Andersen I, Nazim F, Olesen J. Clinical characteristics of 362 patients with familial migraine with aura. *Cephalalgia*. 2004;24(7):564-75.
296. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. *Journal of Cerebral Blood Flow and Metabolism*. 2004;24(12):1352-8.
297. Birk S, Edvinsson L, Olesen J, Kruuse C. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. *European Journal of Pharmacology*. 2004;489(1-2):93-100.
298. Ashina M, Simonsen H, Bendtsen L, Jensen R, Olesen J. Glyceryl trinitrate may trigger endogenous nitric oxide production in patients with chronic tension-type headache. *Cephalalgia*. 2004;24(11):967-72.
299. Thomsen LL, Ostergaard E, Romer SF, Andersen I, Eriksen MK, Olesen J, Russell MB. Sporadic hemiplegic migraine is an aetiologically heterogeneous disorder. *Cephalalgia*. 2003;23(9):921-8.
300. Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. *Neurology*. 2003;60(4):595-601.
301. Thomsen LL, Olesen J, Russell MB. Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. *European Journal of Neurology*. 2003;10(4):421-7.

302. Petersen KA, Nilsson E, Olesen J, Edvinsson L. Only ablutinally applied CGRP induces rat pial artery dilatation in vitro and in vivo. *Cephalalgia*. 2003;23(7):647-.
303. Olesen J, Leonardi M. The burden of brain diseases in Europe. *European Journal of Neurology*. 2003;10(5):471-7.
304. Olesen J, Goadsby P, Steiner T. The International Classification of Headache Disorders: 2nd edition. *Lancet Neurology*. 2003;2(12):720-.
305. Mork H, Ashina M, Bendtsen L, Olesen J, Jensen R. Induction of prolonged tenderness in patients with tension-type headache by means of a new experimental model of myofascial pain. *European Journal of Neurology*. 2003;10(3):249-56.
306. Mork H, Ashina M, Bendtsen L, Olesen J, Jensen R. Experimental muscle pain and tenderness following infusion of endogenous substances in humans. *European Journal of Pain*. 2003;7(2):145-53.
307. Lassen LH, Iversen HK, Olesen J. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. *European Journal of Clinical Pharmacology*. 2003;59(7):499-505.
308. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. *Cephalalgia*. 2003;23(9):877-86.
309. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. *Brain*. 2003;126:241-7.
310. Hjorth LL, Klingenberg IH, Olesen J. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. *EurJClinPharmacol*. 2003;59(7):499-505.
311. Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine: an electronic diary study. *Neurology*. 2003;60(6):935-40.
312. Farkkila M, Olesen J, Dahlof C, Stovner LJ, ter Bruggen JP, Rasmussen S, Muirhead N, Sikes C. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. *Cephalalgia*. 2003;23(6):463-71.
313. Ashina M, Stallknecht B, Bendtsen L, Pedersen JF, Schifter S, Galbo H, Olesen J. Tender points are not sites of ongoing inflammation - in vivo evidence in patients with chronic tension-type headache. *Cephalalgia*. 2003;23(2):109-16.
314. Thomsen LL, Eriksen MK, Romer SF, Andersen I, Ostergaard E, Keiding N, Olesen J, Russell MB. An epidemiological survey of hemiplegic migraine. *Cephalalgia*. 2002;22(5):361-75.
315. Thomsen LL, Eriksen MK, Roemer SF, Andersen I, Olesen J, Russell MB. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. *Brain*. 2002;125:1379-91.
316. Russell MB, Ulrich V, Gervil M, Olesen J. Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. *Headache*. 2002;42(5):332-6.
317. Lykke TL, Kirchmann EM, Faerch RS, Andersen I, Ostergaard E, Keiding N, Olesen J, Russell MB. An epidemiological survey of hemiplegic migraine. *Cephalalgia*. 2002;22(5):361-75.
318. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. *Cephalalgia*. 2002;22(1):54-61.
319. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. *Journal of Cerebral Blood Flow and Metabolism*. 2002;22(9):1124-31.
320. Ashina M, Stallknecht B, Bendtsen L, Pedersen JF, Galbo H, Dalgaard P, Olesen J. In vivo evidence of altered skeletal muscle blood flow in chronic tension-type headache. *Brain*. 2002;125:320-6.
321. Thomsen LL, Olesen J. Nitric oxide in primary headaches. *Current Opinion in Neurology*. 2001;14(3):315-21.
322. Olesen J, Richter S, Scholtz G. The evolutionary transformation of phyllopodous to stenopodous limbs in the Branchiopoda (Crustacea)--is there a common mechanism for early limb development in arthropods? *IntJDevBiol*. 2001;45(8):869-76.

323. Kruuse C, Rybalkin SD, Khurana TS, Jansen-Olesen I, Olesen J, Edvinsson L. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. *European Journal of Pharmacology*. 2001;420(1):55-65.
324. Diener HC, Tfelt-Hansen P, de BF, Ferrari MD, Olesen J, Dahlof C, Mathew N. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. *Cephalalgia*. 2001;21(6):672-9.
325. Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlof C, Mathew N. The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. *Cephalalgia*. 2001;21(6):672-9.
326. Boller F, Sorenson PS, Olesen J. New developments for the European Journal of Neurology. *European Journal of Neurology*. 2001;8(4):289-.
327. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache. *European Journal of Neurology*. 2001;8(2):173-8.
328. Ulrich V, Olesen J, Gervil M, Russell MB. Possible risk factors and precipitants for migraine with aura in discordant twin-pairs: a population-based study. *Cephalalgia*. 2000;20(9):821-5.
329. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. [The significance of genetic and environmental factors for migraine with aura. A genetic epidemiologic study of Danish twins]. *UgeskrLaeger*. 2000;162(2):167-70.
330. Roon KI, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH, Christianssen I, Kleinermans D, Kok JG, Ferrari MD. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. *AnnNeurol*. 2000;47(2):238-41.
331. Olesen J, Jansen-Olesen I. Nitric oxide mechanisms in migraine. *Pathologie Biologie*. 2000;48(7):648-57.
332. Olesen J. Revision of the international headache classification: invitation for comments. *Cephalalgia*. 2000;20(2):73-.
333. Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, ge-Petersen H, Olesen J. Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. *European Journal of Neurology*. 2000;7(6):629-38.
334. Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H, Olesen J. Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. *EurJNeurol*. 2000;7(6):629-38.
335. Kruuse C, Jacobsen TB, Lassen LH, Thomsen LL, Hasselbalch SG, ge-Petersen H, Olesen J. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. *Journal of Cerebral Blood Flow and Metabolism*. 2000;20(9):1372-9.
336. Jensen R, Olesen J. Tension-type headache: an update on mechanisms and treatment. *Current Opinion in Neurology*. 2000;13(3):285-9.
337. Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC, Poole PH. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. *Neurology*. 2000;54(1):156-63.
338. Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC, Sweet R. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. *Cephalalgia*. 2000;20(1):30-8.
339. Christiansen I, Iversen HK, Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. *Cephalalgia*. 2000;20(5):437-44.
340. Christiansen I, Iversen HK, Olesen J. Induction of nitrate tolerance is not a useful treatment in cluster headache. *Cephalalgia*. 2000;20(5):445-54.
341. Christiansen I, Daugaard D, Thomsen LL, Olesen J. Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. *European Journal of Neurology*. 2000;7(4):405-11.

342. Ashina M, Lassen LH, Bendtsen L, Jensen RA, Olesen J. [Inhibition of nitric oxide synthase has an analgesic effect in chronic pain]. *UgeskrLaeger*. 2000;162(2):171-3.
343. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. *Pain*. 2000;86(1-2):133-8.
344. Ashina M, Bendtsen L, Jensen R, Schifter S, Jansen-Olesen I, Olesen J. Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. *Neurology*. 2000;55(9):1335-40.
345. Ashina M, Bendtsen L, Jensen R, Sakai F, Olesen J. Possible mechanisms of glyceryl-trinitrate-induced immediate headache in patients with chronic tension-type headache. *Cephalalgia*. 2000;20(10):919-24.
346. Ashina M, Bendtsen L, Jensen R, Olesen J. Nitric oxide-induced headache in patients with chronic tension-type headache. *Brain*. 2000;123:1830-7.
347. Vorstrup S, Olesen J, Husted SE. Thrombolytic therapy in apoplexy. *Ugeskrift for laeger*. 1999(161):1570-.
348. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. The inheritance of migraine with aura estimated by means of structural equation modelling. *Journal of Medical Genetics*. 1999;36(3):225-7.
349. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. Evidence of a genetic factor in migraine with aura: A population-based Danish twin study. *Annals of Neurology*. 1999;45(2):242-6.
350. Ulrich V, Gervil M, Fenger K, Olesen J, Russell MB. The prevalence and characteristics of migraine in twins from the general population. *Headache*. 1999;39(3):173-80.
351. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. *Neurology*. 1999;52(7):1479-84.
352. Sellebjerg F, Nielsen HS, Frederiksen JJ, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. *Neurology*. 1999;52(7):1479-84.
353. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. [Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis]. *UgeskrLaeger*. 1999;161(48):6625-9.
354. Russell MB, Ostergaard S, Bendtsen L, Olesen J. Familial occurrence of chronic tension-type headache. *Cephalalgia*. 1999;19(4):207-10.
355. Olesen J. Prospective study is needed to determine what clinical practice in migraine should be. *British Medical Journal*. 1999;318(7196):1485-6.
356. Olesen J. European Federation of Neurological Societies (EFNS) guideline papers. *European Journal of Neurology*. 1999;6(3):257-8.
357. Gervil M, Ulrich V, Kyvik KO, Olesen J, Russell MB. Migraine without aura: A population-based twin study. *Annals of Neurology*. 1999;46(4):606-11.
358. Gervil M, Ulrich V, Kaprio J, Olesen J, Russell MB. The relative role of genetic and environmental factors in migraine without aura. *Neurology*. 1999;53(5):995-9.
359. Friederichs H, Olesen J, Russell MB. [Familial occurrence of chronic tension headache]. *UgeskrLaeger*. 1999;161(5):576-8.
360. Culebras A, Olesen J. Are neurologists cost-effective? *European Journal of Neurology*. 1999;6:S1-S2.
361. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. *Cephalalgia*. 1999;19(7):660-7.
362. Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial. *Lancet*. 1999;353(9149):287-9.
363. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Increased plasma levels of calcitonin gene-related peptide in migraine. *Cephalalgia*. 1999;19(4):346-.
364. Ashina M, Bendtsen L, Jensen R, Sakai F, Olesen J. Muscle hardness in patients with chronic tension-type headache: relation to actual headache state. *Pain*. 1999;79(2-3):201-5.
365. Ashina M, Bendtsen L, Jensen R, Lassen LH, Sakai F, Olesen J. Possible mechanisms of action of nitric oxide synthase inhibitors in chronic tension-type headache. *Brain*. 1999;122:1629-35.

366. Ashina M, Bendtsen L, Jensen R, Ekman R, Olesen J. Plasma levels of substance P, neuropeptide Y and vasoactive intestinal polypeptide in patients with chronic tension-type headache. *Pain*. 1999;83(3):541-7.
367. Thomsen LL, Olesen J, Russell MB. Familial hemiplegic migraine. *Ugeskrift for laeger*. 1998(18):342-8.
368. Thomsen LL, Olesen J. Nitric oxide theory of migraine. *Clinical Neuroscience*. 1998;5(1):28-33.
369. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. *Neurology*. 1998;51(2):529-34.
370. Russell MB, Iselius L, Ostergaard S, Olesen J. Inheritance of chronic tension-type headache investigated by complex segregation analysis. *Human Genetics*. 1998;102(2):138-40.
371. Petersen AA, Sellebjerg F, Frederiksen J, Olesen J, Vejlsgaard GL. Soluble ICAM-1, demyelination, and inflammation in multiple sclerosis and acute optic neuritis. *Journal of Neuroimmunology*. 1998;88(1-2):120-7.
372. Olesen J, Zberg G, Vestergaard P. Disorders of the brain: costs, recent progress and future possibilities. *EurJNeurol*. 1998;5(5):425-30.
373. Olesen J, Qberg G, Vestergaard P. Activities in the Danish Year of the Brain 1997. *European Journal of Neurology*. 1998;5(6):619-24.
374. Olesen J, Oberg G, Vestergaard P. Activities in the Danish Year of the Brain 1997. *EurJNeurol*. 1998;5(6):619-24.
375. Olesen J, Oberg G, Vestergaard P. Disorders of the brain: costs, recent progress and future possibilities. *European Journal of Neurology*. 1998;5(5):425-30.
376. Olesen J, Oberg G, Vestergaard P. Year of the brain in European countries. Background and organization. *European Journal of Neurology*. 1998;5(4):325-8.
377. Olesen J. Neuroimaging in Europe - the present and the future. *European Journal of Neurology*. 1998;5(1):3-.
378. Olesen J. Regional cerebral blood flow and oxygen metabolism during migraine with and without aura. *Cephalalgia*. 1998(18):2-4.
379. Olesen J. Headache. *Ugeskrift for laeger*. 1998(160):4397-8.
380. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J. Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. *Cephalalgia*. 1998;18(1):23-6.
381. Ogilvie A, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CAD, Goodwin GM, Harmar AJ, Olesen J. Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. *Cephalalgia*. 1998;18(1):23-6.
382. Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, Olesen J. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. *Cephalalgia*. 1998;18(1):27-32.
383. Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. *Headache*. 1998;38(1):10-7.
384. Jensen K, Ankjaer-Jensen A, Hansen PE, Holm-Thomsen OE, Korsgaard AG, Krabbe AA, Nielsen MR, Olesen J, Tfelt-Hansen P. Guidelines for the management of headache. *Cephalalgia*. 1998;18(1):9-22.
385. Gervil M, Ulrich V, Olesen J, Russell MB. Screening for migraine in the general population: validation of a simple questionnaire. *Cephalalgia*. 1998;18(6):342-8.
386. Daugaard D, Thomsen LL, Olesen J. No relation between cephalic venous dilatation and pain in migraine. *Journal of Neurology Neurosurgery and Psychiatry*. 1998;65(2):260-2.
387. Dahlof C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J, Boswell D, Fuseau E, Hassani H, Winter P. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. *European Journal of Neurology*. 1998;5(5):469-77.

388. Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM, Klein KB. Zolmitriptan, a 5-HT<sub>1B/1D</sub> receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. *European Journal of Neurology*. 1998;5(6):535-43.
389. Ashina M, Bendtsen L, Jensen R, Sakai F, Olesen J. Measurement of muscle hardness: a methodological study. *Cephalalgia*. 1998;18(2):106-11.
390. Adelman JU, Baumel B, Cady RK, Baker CC, Couch JR, Dalessio DJ, Diamond S, Elkind AH, Foster CA, Goldstein J, Katz DA, Kirchner JR, Klapper JA, Kudrow DB, Kunkel R, Landy SH, Licht JM, Linder SL, Loder E, Markley HG, Mathew NT, Meyer JS, Nett R, Packard RC, Perse T, Peters KS, Ramadan NM, Rapoport AM, Rosing HS, Sadowsky C, Saper JR, Sharfman MI, Silberstein SD, Singer RP, Smith R, Solomon G, Solomon S, Stark SR, Swanson JW, Taylor FR, Tepper SJ, Tuchman MM, Vijayan N, Walker J, Ward T, Warner JS, Wendt JK, Winner P, Beran P, Black A, Donnan G, Herkes G, Lord G, Zagami A, Baumhackl U, Broussalis T, Klingler D, Ladurner G, Jacquy J, Louis P, Schoenen J, Gawel MJ, Hansen PE, Jensen K, Pedersen KK, Korsgaard A, Lademann A, Olesen J, Simonsen N, Sorensen PS, Jensen TS, Tfelt-Hansen P, Kaasik AE, Zupping R, Farkkila M, Haanpaa M, Havanka H, Hedman C, Ilmavirta M, Kinnunen E, Liukkonen J, Partinen M, Rautakorpi I, Reunanen M, Sako E, Seppa JM, Barege M, Chazot G, Colombani JP, Dujardin M, Fabre N, Giacomino A, Geraud G, Henry P, Jogeix, Laporte A, Lichtblau, Massiou H, Mazingue D, Mihout B, Petit H, Veyrie M, Vilarem H, Wilmann JF, Beckmann-Reinholdt A, Diener HC, Evers S, Gobel H, Klepel H, Kuhl W, Langohr HD, Neu I, Paulus W, Peikert A, Pfaffenrath V, Scholz E, Straube A, Witte OW, Harmousi S, Karageorgiou C, Milonas I, Giacomino M, Nappi G, ter Berg JWM, Sanders EACM, van der Zwan JL, Edland A, Engelsens B, Gronning M, Haldorsen T, Hodnebo A, Larsen JP, Dornzal T, Prusinski A, Szczudlik A, Naya MG, Granell AN, Lainez JM, Leira R, Liano H, Pascual J, Boivie J, Dahlof C, Edvinsson L, Hardebo JE, Nilsson H, Waldenlind E, Isler HR, Crawford P, Dowson AJ, Findley L, Gross M, Hawkes CH, Jestico J, Rolan P, Steiner TJ, Wilkinson M, Wagner G. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. *Headache*. 1998;38(3):173-83.
391. Ulrich V, Russell MB, Ostergaard S, Olesen J. Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. *American Journal of Medical Genetics*. 1997;74(4):395-7.
392. Thomsen LL, Olesen J. A pivotal role of nitric oxide in migraine pain. *Frontiers of Neurology*. 1997;835:363-72.
393. Thomsen LL, Brennum J, Iversen HK, Olesen J. [Effects of nitrogen oxide donor glyceryl trinitrate on pressure pain threshold in humans]. *UgeskrLaeger*. 1997;159(30):4645-8.
394. Ostergaard S, Russell MB, Bendtsen L, Olesen J. Comparison of first degree relatives and spouses of people with chronic tension headache. *British Medical Journal*. 1997;314(7087):1092-3.
395. Olesen J, <sup>™</sup>berg G, Vestergaard P. Hjerne†ret 1997 i Danmark. *Ugeskrift for laeger*. 1997(4):463-9.
396. Olesen J, <sup>™</sup>berg G, Vestergaard P. Aktiviteter i Hjerne†ret 1997 i Danmark. *Ugeskrift for laeger*. 1997(6):798-802.
397. Olesen J, Thomsen LL, Russell MB. Mechanisms of pain and genetics in migraine. *Ugeskrift for laeger*. 1997(159):2075-6.
398. Olesen J. The sun shines on neurology in Europe but for how long? *European Journal of Neurology*. 1997;4(2):101-.
399. Olesen J. Hjerneforskning: Den sorte ´ske er lukket op. *Ugeskrift for laeger*. 1997(4):401-2.
400. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. *Lancet*. 1997;349(9049):401-2.
401. Jansen-Olesen I, Ottosson A, Cantera L, Strunk S, Lassen LH, Olesen J, Mortensen A, Engel U, Edvinsson L. Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H<sub>1</sub>- and H<sub>2</sub>-receptors by RT-PCR. *BrJPharmacol*. 1997;121(1):41-8.

402. Jansen Olesen I, Ottosson A, Cantera L, Strunk S, Lassen LH, Olesen J, Mortensen A, Engel U, Edvinsson L. Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H-1- and H-2-receptors by RT-PCR. *Br J of Pharmacol.* 1997;121(1):41-8.
403. Goadsby PJ, Olesen J. Increasing the options for effective migraine management. *Neurology.* 1997;48(3):S1-S3.
404. Frederiksen JL, Larsson HBW, Christiansen P, Olesen J. Assessment of MRI criteria for abnormal brain MRI in acute monosymptomatic optic neuritis. Comparison to findings in healthy persons. *European Journal of Neurology.* 1997;4(6):561-6.
405. Burnet PWJ, Harrison PJ, Goodwin GM, Battersby S, Ogilvie AD, Olesen J, Russell MB. Allelic variation in the serotonin 5-HT<sub>2C</sub> receptor gene and migraine. *Neuroreport.* 1997;8(12):2651-3.
406. Burnet PW, Harrison PJ, Goodwin GM, Battersby S, Ogilvie AD, Olesen J, Russell MB. Allelic variation in the serotonin 5-HT<sub>2C</sub> receptor gene and migraine. *Neuroreport.* 1997;8(12):2651-3.
407. Bendtsen L, Norregaard J, Jensen R, Olesen J. Evidence of qualitatively altered nociception in patients with fibromyalgia. *Arthritis and Rheumatism.* 1997;40(1):98-102.
408. Bendtsen L, Jensen RA, Olesen J. [Decreased pain threshold and tolerance in patients with chronic tension headache]. *UgeskrLaeger.* 1997;159(29):4521-5.
409. Bendtsen L, Jensen RA, Olesen J. Tension headache. *Ugeskrift for laeger.* 1997(159):4965-8.
410. Bendtsen L, Jensen R, Hindberg I, Gammeltoft S, Olesen J. Serotonin metabolism in chronic tension-type headache. *Cephalalgia.* 1997;17(8):843-8.
411. Ulrich V, Russell MB, Jensen R, Olesen J. A comparison of tension-type headache in migraineurs and in non-migraineurs: a population-based study. *Pain.* 1996;67(2-3):501-6.
412. Thomsen LL, Dixon R, Lassen LH, Gibbens M, Langemark M, Bendtsen L, Daugaard D, Olesen J. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. *Cephalalgia.* 1996;16(4):270-5.
413. Thomsen LL, Dixon R, Lassen LH, Gibbens M, Langemark M, Bendtsen L, Daugaard D, Olesen J. 311C90 (Zolmitriptan\*), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. *Cephalalgia.* 1996;16(4):270-5.
414. Thomsen LL, Daugaard D, Iversen HK, Olesen J. Normal radial artery dilatation during reactive hyperaemia in migraine without aura. *Endothelium.* 1996(4):199-206.
415. Thomsen LL, Brennum J, Iversen HK, Olesen J. Effect of a nitric oxide donor (glyceryl trinitrate) on nociceptive thresholds in man. *Cephalalgia.* 1996;16(3):169-74.
416. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. [Prevalence and sex distribution of different forms of migraine]. *UgeskrLaeger.* 1996;158(10):1369-72.
417. Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: A study of four hundred and eighty-four male and female migraineurs from the general population. *Cephalalgia.* 1996;16(4):239-45.
418. Russell MB, Olesen J. Migrainous disorder and its relation to migraine without aura and migraine with aura. A genetic epidemiological study. *Cephalalgia.* 1996;16(6):431-5.
419. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. *Brain.* 1996;119:355-61.
420. Russell MB, Olesen J. Migraine associated with head trauma. *European Journal of Neurology.* 1996(3):424-8.
421. Russell MB, Iselius L, Olesen J. Migraine without aura and migraine with aura are inherited disorders. *Cephalalgia.* 1996;16(5):305-9.
422. Russell MB, Fenger K, Olesen J. The family history of migraine. Direct versus indirect information. *Cephalalgia.* 1996;16(3):156-60.

423. Olesen J, Rasmussen BK. The International Headache Society classification of chronic daily and near-daily headaches: A critique of the criticism. *Cephalalgia*. 1996;16(6):407-11.
424. Olesen J. The International Headache Society classification and diagnostic criteria are valid and extremely useful. *Cephalalgia*. 1996;16(5):293-5.
425. Olesen J. International headache research seminars: What are they and how should they be used? *Cephalalgia*. 1996;16(5):344-5.
426. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. *EurJ Clin Pharmacol*. 1996;49(5):335-9.
427. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine - Support for the NO-hypothesis of migraine. *European Journal of Clinical Pharmacology*. 1996;49(5):335-9.
428. Lassen LH, Heinig JH, Oestergaard S, Olesen J. Histamine inhalation is a specific but insensitive laboratory test for migraine. *Cephalalgia*. 1996;16(8):550-3.
429. Jensen R, Olesen J. Initiating mechanisms of experimentally induced tension-type headache. *Cephalalgia*. 1996;16(3):175-82.
430. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. *Cephalalgia*. 1996;16(6):412-8.
431. Goldstein J, Dahlof CGH, Diener HC, Olesen J, Schellens R, Senard JM, Simard D, Steiner TJ. Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study. *Cephalalgia*. 1996;16(7):497-502.
432. Goadsby PJ, Olesen J. Diagnosis and management of migraine. *BMJ*. 1996;312(7041):1279-83.
433. Frederiksen JL, Petrera J, Larsson HB, Stigsby B, Olesen J. Serial MRI, VEP, SEP and biotesiometry in acute optic neuritis: value of baseline results to predict the development of new lesions at one year follow up. *Acta Neurol Scand*. 1996;93(4):246-52.
434. Frederiksen JL, Olesen J, Larsson HB, Petrera J, Sellebjerg FT. Acute unilateral papillitis versus retrobulbar neuritis: relation to multiple sclerosis. *Mult Scler*. 1996(1):223-7.
435. Frederiksen JL, Larsson HBW, Christiansen P, Sellebjerg FT, Olesen J. Blood-brain barrier impairment in acute optic neuritis evaluated by Gadolinium-DTPA enhanced MRI and CSF studies. *European Journal of Neurology*. 1996;3(6):560-6.
436. Brennum J, Brinck T, Schriver L, Wanscher B, Sorensen PS, Tfelt Hansen P, Olesen J. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. *European Journal of Neurology*. 1996;3(1):23-8.
437. Bendtsen L, Jensen R, Olesen J. Amitriptyline, a combined serotonin and noradrenaline re-uptake inhibitor, reduces exteroceptive suppression of temporal muscle activity in patients with chronic tension-type headache. *Electromyography and Motor Control-Electroencephalography and Clinical Neurophysiology*. 1996;101(5):418-22.
438. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. *Journal of Neurology Neurosurgery and Psychiatry*. 1996;61(3):285-90.
439. Bendtsen L, Jensen R, Olesen J. Qualitatively altered nociception in chronic myofascial pain. *Pain*. 1996;65(2-3):259-64.
440. Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. *Archives of Neurology*. 1996;53(4):373-6.
441. Bendtsen L, Jensen R, Brennum J, Arendt-Nielsen L, Olesen J. Exteroceptive suppression of temporal muscle activity is normal in chronic tension-type headache and not related to actual headache state. *Cephalalgia*. 1996;16(4):251-6.
442. Bendtsen L, Jensen R, Brennum J, Arendt-Nielsen L, Olesen J. Exteroceptive suppression of temporal muscle activity is normal in chronic tension-type headache and not related to actual headache state. *Cephalalgia*. 1996;16(4):251-6.

443. Thomsen LL, Olesen J. The autonomic nervous system and the regulation of arterial tone in migraine. *ClinAutonRes*. 1995;5(5):243-50.
444. Thomsen LL, Iversen HK, Olesen J. Increased cerebrovascular pCO<sub>2</sub> reactivity in migraine with aura - a transcranial Doppler study during hyperventilation. *Cephalalgia*. 1995;15(3):211-5.
445. Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. *Cephalalgia*. 1995;15(2):109-16.
446. Thomsen LL, Iversen HK, Olesen J. Increased Cerebrovascular Pco<sub>2</sub> Reactivity in Migraine with Aura - A Transcranial Doppler Study During Hyperventilation. *Cephalalgia*. 1995;15(3):211-5.
447. Thomsen LL, Iversen HK, Olesen J. Cerebral Blood-Flow Velocities Are Reduced During Attacks of Unilateral Migraine Without Aura. *Cephalalgia*. 1995;15(2):109-16.
448. Thomsen LL, Iversen HK, Boesen F, Olesen J. Transcranial Doppler and cardiovascular responses during cardiovascular autonomic tests in migraineurs during and outside attacks. *Brain*. 1995;118 ( Pt 5):1319-27.
449. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and Sex-Ratio of the Subtypes of Migraine. *International Journal of Epidemiology*. 1995;24(3):612-8.
450. Russell MB, Olesen J. Increased familial risk and evidence of genetic factor in migraine. *BMJ*. 1995;311(7004):541-4.
451. Russell MB, Olesen J. Increased Familial Risk and Evidence of Genetic-Factor in Migraine. *British Medical Journal*. 1995;311(7004):541-4.
452. Russell MB, Iselius L, Olesen J. Inheritance of Migraine Investigated by Complex Segregation Analysis. *Human Genetics*. 1995;96(6):726-30.
453. Russell MB, Holm-Thomsen OE, Nielsen MR, Cleal A, Pilgrim AJ, Olesen J. [Sumatriptan treatment of migraine in general practice. A randomized, double-blind, placebo-controlled cross-over study]. *UgeskrLaeger*. 1995;157(16):2320-3.
454. Olesen J, Thomsen LL, Lassen LH, Olesen J. The nitric oxide hypothesis of migraine and other vascular headaches. *Cephalalgia*. 1995;15(2):94-100.
455. Olesen J, Rasmussen BK. Classification of primary headaches. *Biomedicine & Pharmacotherapy*. 1995;49(10):446-51.
456. Olesen J. Spreading Cerebral Hypoperfusion During Migraine Headache. *New England Journal of Medicine*. 1995;332(22):1517-8.
457. Olesen J. Analgesic Headache. *British Medical Journal*. 1995;310(6978):479-80.
458. Olesen J. New Developments in migraine diagnosis and treatment. *Japanese Journal of Pain*. 1995(2):365-79.
459. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H<sub>1</sub>-receptor. Support for the NO hypothesis of migraine. *Neuroreport*. 1995;6(11):1475-9.
460. Langemark M, Bach FW, Ekman R, Olesen J. Increased cerebrospinal fluid Met-enkephalin immunoreactivity in patients with chronic tension-type headache. *Pain*. 1995;63(1):103-7.
461. Bendtsen L, Jensen R, Olesen J. Pressure-sensitive devices. *Pain*. 1995;62(2):250.
462. Bendtsen L, Jensen R, Jensen NK, Olesen J. Pressure-controlled palpation: a new technique which increases the reliability of manual palpation. *Cephalalgia*. 1995;15(3):205-10.
463. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) induces genuine migraine attacks. *European Journal of Neurology*. 1994(1):73-80.
464. Thomsen LL, Iversen HK, Lassen LH, Olesen J. The Role of Nitric-Oxide in Migraine Pain - Therapeutic Implications. *Cns Drugs*. 1994;2(6):417-22.
465. Russell MB, Iversen HK, Olesen J. Improved Description of the Migraine Aura by A Diagnostic Aura Diary. *Cephalalgia*. 1994;14(2):107-17.
466. Russell MB, Holm-Thomsen OE, Rishoj NM, Cleal A, Pilgrim AJ, Olesen J. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. *Cephalalgia*. 1994;14(4):291-6.

467. Rasmussen BK, Olesen J. Epidemiology of Migraine and Tension-Type Headache. *Current Opinion in Neurology*. 1994;7(3):264-71.
468. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. *Trends PharmacolSci*. 1994;15(5):149-53.
469. Olesen J, Thomsen LL, Iversen H. Nitric-Oxide Is A Key Molecule in Migraine and Other Vascular Headaches. *Trends in Pharmacological Sciences*. 1994;15(5):149-53.
470. Olesen J, Lipton RB. Migraine Classification and Diagnosis - International-Headache-Society Criteria. *Neurology*. 1994;44(6):6-10.
471. Olesen J, Jensen R, Iversen H. Frontlinier i hovedpineforskningen. *M†nedsskr Prakt L'gegern*. 1994(4):421-36.
472. Olesen J. Understanding the Biologic Basis of Migraine. *New England Journal of Medicine*. 1994;331(25):1713-4.
473. Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. *Headache*. 1994;34(1):20-4.
474. Jensen R, Fuglsang-Frederiksen A, Olesen J. Quantitative surface EMG of pericranial muscles in headache. A population study. *ElectroencephalogrClinNeurophysiol*. 1994;93(5):335-44.
475. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. *Neurology*. 1994;44(4):647-51.
476. Iversen HK, Olesen J. Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide. *Cephalalgia*. 1994;14(6):437-42.
477. Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. *Cephalalgia*. 1994;14(1):47-54.
478. Friberg L, Olesen J, Lassen NA, Olsen TS, Karle A. Cerebral oxygen extraction, oxygen consumption, and regional cerebral blood flow during the aura phase of migraine. *Stroke*. 1994;25(5):974-9.
479. Friberg L, Olesen J, Iversen H, Nicolic I, Sperling B, Lassen NA, Olsen TS, Tfelt-Hansen P. Interictal "patchy" regional cerebral blood flow pattern in migraine patients. A single photon emission computerized tomographic study. *European Journal of Neurology*. 1994(1):35-44.
480. Bendtsen L, Jensen R, Jensen NK, Olesen J. Muscle palpation with controlled finger pressure: new equipment for the study of tender myofascial tissues. *Pain*. 1994;59(2):235-9.
481. Bates D, Ashford E, Dawson R, Ensink FBM, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P. Subcutaneous Sumatriptan During the Migraine Aura. *Neurology*. 1994;44(9):1587-92.
482. Bach FW, Langemark M, Ekman R, Rehfeld JF, Schifter S, Olesen J. Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. *Neuropeptides*. 1994;27(2):129-36.
483. Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. *Cephalalgia*. 1993;13(6):395-9.
484. Tfelt-Hansen P, Ferrari MD, Olesen J. Association between sumatriptan and stroke. *Lancet*. 1993;342(8866):303.
485. Russell MB, Olesen J. The Genetics of Migraine Without Aura and Migraine with Aura. *Cephalalgia*. 1993;13(4):245-8.
486. Russell MB, Hilden J, Sorensen SA, Olesen J. Familial Occurrence of Migraine Without Aura and Migraine with Aura. *Neurology*. 1993;43(7):1369-73.
487. Rasmussen BK, Olesen J. Migraine epidemiology. *Cephalalgia*. 1993(13):216-7.
488. Olesen J, Welch KMA, Carolei A, Easton JD. Treatment to Prevent Migraine-Related Stroke. *Cerebrovascular Diseases*. 1993;3(4):244-7.
489. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. *Neuroreport*. 1993;4(8):1027-30.

490. Olesen J, Friberg L, Olsen TS, Andersen AR, Lassen NA, Hansen PE, Karle A. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. *Brain*. 1993;116 ( Pt 1):187-202.
491. Olesen J. IHS Classification: present and future. *Cephalalgia*. 1993;13 Suppl 12:94.
492. Nielsen TH, Iversen HK, Tfelt-Hansen P, Olesen J. Small arteries can be accurately studied in vivo, using high frequency ultrasound. *Ultrasound MedBiol*. 1993;19(9):717-25.
493. Langemark M, Bach FW, Jensen TS, Olesen J. Decreased Nociceptive Flexion Reflex Threshold in Chronic Tension-Type Headache. *Archives of Neurology*. 1993;50(10):1061-4.
494. Jensen R, Rasmussen BK, Pedersen B, Olesen J. Muscle tenderness and pressure pain thresholds in headache. A population study. *Pain*. 1993;52(2):193-9.
495. Jensen R, Rasmussen BK, Pedersen B, Lous I, Olesen J. Prevalence of oromandibular dysfunction in a general population. *J Orofac Pain*. 1993(7):175-82.
496. Jensen R, Fuglsang-Frederiksen A, Olesen J. Quantitative surface EMG of pericranial muscles. Reproducibility and variability. *ElectroencephalogrClinNeurophysiol*. 1993;89(1):1-9.
497. Jansen I, Olesen J, Edvinsson L. 5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. *Acta Physiol Scand*. 1993;147(2):141-50.
498. Iversen HK, Nielsen TH, Tfelt-Hansen P, Olesen J. Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin. *EurJClinPharmacol*. 1993;44(1):47-50.
499. Brinck T, Hansen K, Olesen J. Headache Resembling Tension-Type Headache As the Single Manifestation of Lyme Neuroborreliosis. *Cephalalgia*. 1993;13(3):207-9.
500. Bendtsen L, Jensen R, Brennum J, Arendt-Nielsen L, Olesen J. Exteroceptive suppression periods in jaw-closing muscles. Variability and relation to experimental pain and sustained muscle contraction. *Cephalalgia*. 1993;13(3):184-91.
501. Russell MB, Rasmussen BK, Brennum J, Iversen HK, Jensen RA, Olesen J. Presentation of a new instrument: the diagnostic headache diary. *Cephalalgia*. 1992;12(6):369-74.
502. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. *Cephalalgia*. 1992;12(4):221-8.
503. Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. *Neurology*. 1992;42(6):1225-31.
504. Rasmussen BK, Jensen R, Schroll M, Olesen J. Interrelations between migraine and tension-type headache in the general population. *ArchNeurol*. 1992;49(9):914-8.
505. Rasmussen BK, Jensen R, Schroll M, Olesen J. Interrelations Between Migraine and Tension-Type Headache in the General-Population. *Archives of Neurology*. 1992;49(9):914-8.
506. Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. *JEpidemiolCommunity Health*. 1992;46(4):443-6.
507. Petersen KL, Brennum J, Olesen J. Evaluation of pericranial myofascial nociception by pressure algometry. Reproducibility and factors of variation. *Cephalalgia*. 1992;12(1):33-7.
508. Olesen J. Cerebral blood flow in migraine with aura. *PatholBiol(Paris)*. 1992;40(4):318-24.
509. Olesen J. The Mechanisms of Migraine. *Recherche*. 1992;23(240):160-8.
510. Jensen R, Rasmussen BK, Pedersen B, Lous I, Olesen J. Cephalic muscle tenderness and pressure pain threshold in a general population. *Pain*. 1992;48(2):197-203.
511. Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. *Peptides*. 1992;13(3):527-36.
512. Jansen I, Edvinsson L, Mortensen A, Olesen J. Sumatriptan Is A Potent Vasoconstrictor of Human Dural Arteries Via A 5-Ht1-Like Receptor. *Cephalalgia*. 1992;12(4):202-5.

513. Iversen HK, Nielsen TH, Garre K, Tfelt-Hansen P, Olesen J. Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate. *EurJ Clin Pharmacol.* 1992;42(1):31-5.
514. Frederiksen JL, Larsson HBW, Olesen J. Correlation of Magnetic-Resonance-Imaging and Csf Findings in Patients with Acute Monosymptomatic Optic Neuritis. *Acta Neurologica Scandinavica.* 1992;86(3):317-22.
515. Brennum J, Kjeldsen M, Olesen J. The 5-Ht1-Like Agonist Sumatriptan Has A Significant Effect in Chronic Tension-Type Headache. *Cephalalgia.* 1992;12(6):375-9.
516. Bach FW, Langemark M, Secher NH, Olesen J. Plasma and cerebrospinal fluid beta-endorphin in chronic tension-type headache. *Pain.* 1992;51(2):163-8.
517. Tfelt-Hansen P, Iversen HK, Olesen J. Subcutaneous Sumatriptan in Acute Migraine. *Jama-Journal of the American Medical Association.* 1991;266(19):2703-4.
518. Soelberg Sørensen P, Larsen BH, Rasmussen MJK, Kinge E, Iversen H, Alslev T, Nørh P, Pedersen KK, Schrøder P, Lademann A, Olesen J. Flunarizine versus metoprolol in migraine prophylaxis: A double-blind randomized parallel group study of efficacy and tolerability. *Headache.* 1991;31(1):650-7.
519. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population--a prevalence study. *J Clin Epidemiol.* 1991;44(11):1147-57.
520. Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. *Cephalalgia.* 1991;11(3):129-34.
521. Rasmussen BK, Jensen R, Olesen J. Questionnaire Versus Clinical Interview in the Diagnosis of Headache. *Headache.* 1991;31(5):290-5.
522. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J. Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. *Peptides.* 1991;12(2):333-7.
523. Ottosson ALP, Jansen I, Langemark M, Olesen J, Edvinsson L. Histamine-Receptors in the Isolated Human Middle Meningeal Artery - A Comparison with Cerebral and Temporal Arteries. *Cephalalgia.* 1991;11(4):183-8.
524. Olesen J, Jensen R. Getting away from simple muscle contraction as a mechanism of tension-type headache. *Pain.* 1991;46(2):123-4.
525. Olesen J, Edvinsson L. Migraine: a research field matured for the basic neurosciences. *Trends Neurosci.* 1991;14(1):3-5.
526. Olesen J, Edvinsson L. Migraine - A Research Field Matured for the Basic Neurosciences. *Trends in Neurosciences.* 1991;14(1):3-5.
527. Olesen J. Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. *Cerebrovasc Brain Metab Rev.* 1991;3(1):1-28.
528. Olesen J. Clinical and Pathophysiological Observations in Migraine and Tension-Type Headache Explained by Integration of Vascular, Supraspinal and Myofascial Inputs. *Pain.* 1991;46(2):125-32.
529. Olesen J. A Review of Current Drugs for Migraine. *Journal of Neurology.* 1991;238:S23-S7.
530. Loldrup D, Langemark M, Hansen HJ, Kastrop M, Jeppesen K, Bonnevie O, Elsborg L, Olesen J, Bech P. The Validity of the Melancholia Scale (MES) in predicting outcome of antidepressants in chronic idiopathic pain disorders. *European Psychiatry.* 1991(6):119-25.
531. Larsson HBW, Christiansen P, Jensen M, Frederiksen J, Heltberg A, Olesen J, Henriksen O. Localized In vivo Proton Spectroscopy in the Brain of Patients with Multiple-Sclerosis. *Magnetic Resonance in Medicine.* 1991;22(1):23-31.
532. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. *Lancet.* 1991;338(8758):13-7.
533. Frederiksen JL, Larsson HBW, Ottovay E, Stigsby B, Olesen J. Acute Optic Neuritis with Normal Visual-Acuity - Comparison of Symptoms and Signs with Psychophysiological, Electrophysiological and Magnetic-Resonance-Imaging Data. *Acta Ophthalmologica.* 1991;69(3):357-66.

534. Frederiksen JL, Larsson HBW, Olesen J, Stigsby B. Mri, Vep, Sep and Biothesiometry Suggest Monosymptomatic Acute Optic Neuritis to be A 1St Manifestation of Multiple-Sclerosis. *Acta Neurologica Scandinavica*. 1991;83(5):343-50.
535. Olesen J, Rasmussen BK. Management of Acute Nonvascular Headache - the Danish Experience. *Headache*. 1990;30:541-4.
536. Langemark M, Loldrup D, Bech P, Olesen J. Clomipramine and Mianserin in the Treatment of Chronic Tension Headache - A Double-Blind, Controlled-Study. *Headache*. 1990;30(3):118-21.
537. Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, Karle A. Timing and Topography of Cerebral Blood-Flow, Aura, and Headache During Migraine Attacks. *Annals of Neurology*. 1990;28(6):791-8.
538. Langemark M, Loldrup D, Bech P, Olesen J. Clomipramine and mianserin in the treatment of chronic tension headache. A double-blind, controlled study. *Headache*. 1990;30(3):118-21.
539. Olesen J. Calcium-Antagonists in the Therapy of Migraine. *European Journal of Pharmacology*. 1990;183(1):57-8.
540. Olesen J. Calcium-Antagonists in Migraine and Vertigo - Possible Mechanisms of Action and Review of Clinical-Trials. *European Neurology*. 1990;30:31-4.
541. Olesen J. The classification and diagnosis of headache disorders. *Headache*. 1990(8):793-9.
542. Olesen J. Headache diagnosis and vascular pathophysiology. *Clin Neurol*. 1990(30):1317-22.
543. Lisby G, Frederiksen J, Olesen J, Reitz MS, Jr. Absence of HTLV-I DNA in blood from patients with multiple sclerosis. *AIDS ResHumRetroviruses*. 1990;6(11):1219.
544. Larsen BH, Christiansen LV, Andersen B, Olesen J. Randomized Double-Blind Comparison of Tolfenamic Acid and Paracetamol in Migraine. *Acta Neurologica Scandinavica*. 1990;81(5):464-7.
545. Langemark M, Jensen K, Olesen J. Temporal muscle blood flow in chronic tension-type headache. *ArchNeurol*. 1990;47(6):654-8.
546. Jensen K, Tuxen C, Pedersen-Bjergaard U, Jansen I, Edvinsson L, Olesen J. Pain, wheal and flare in human forearm skin induced by bradykinin and 5-hydroxytryptamine. *Peptides*. 1990;11(6):1133-8.
547. Jensen K, Tuxen C, Pedersenbjergaard U, Jansen I, Edvinsson L, Olesen J. Pain and Tenderness in Human Temporal Muscle Induced by Bradykinin and 5-Hydroxytryptamine. *Peptides*. 1990;11(6):1127-32.
548. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. *Lancet*. 1990;336(8719):837-9.
549. Iversen HK, Langemark M, Andersson PG, Hansen PE, Olesen J. Clinical characteristics of migraine and episodic tension-type headache in relation to old and new diagnostic criteria. *Headache*. 1990;30(8):514-9.
550. Iversen HK, Langemark M, Andersson PG, Hansen PE, Olesen J. Clinical Characteristics of Migraine and Episodic Tension-Type Headache in Relation to Old and New Diagnostic-Criteria. *Headache*. 1990;30(8):514-9.
551. Hansen SL, Borelli-Moller L, Strange P, Nielsen BM, Olesen J. Ophthalmoplegic migraine: diagnostic criteria, incidence of hospitalization and possible etiology. *Acta NeurolScand*. 1990;81(1):54-60.
552. Tuxen C, Jensen K, Kjeldsen M, Edvinsson L, Jansen I, Olesen J. Effect of neurokinin A on human temporal muscle blood flow. *Peptides*. 1989;10(5):921-4.
553. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J. Algesia and local responses induced by neurokinin A and substance P in human skin and temporal muscle. *Peptides*. 1989;10(6):1147-52.
554. Olesen J. 5-HT 1 -Like Receptor Agonism As A Novel-Approach to the Treatment of Acute Migraine. *Cephalalgia*. 1989;9:97-101.
555. Olesen J. New International Headache Classification. *Neuroepidemiology*. 1989;8(2):53-5.
556. Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. *Psychopharmacology (Berl)*. 1989;99(1):1-7.

557. Larsson HBW, Frederiksen J, Petersen J, Nordenbo A, Zeeberg I, Henriksen O, Olesen J. Assessment of Demyelination, Edema, and Gliosis by In vivo Determination of T1 and T2 in the Brain of Patients with Acute Attack of Multiple-Sclerosis. *Magnetic Resonance in Medicine*. 1989;11(3):337-48.
558. Langemark M, Jensen K, Jensen TS, Olesen J. Pressure Pain Thresholds and Thermal Nociceptive Thresholds in Chronic Tension-Type Headache. *Pain*. 1989;38(2):203-10.
559. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. *Pain*. 1989;38(1):17-24.
560. Gelmers HJ, Henry P, Lucas J, Holtlarsen B, Olesen J, Behan P, Exhenry C, Regli F, Festenstein R, Lance F, Parkes C, Wilkinson M, Russell D, Svare A, Havankakanniainen H, Cavallini A, Micieli G, Nappi G, Tassorelli C, Bes A, Fabre N, Schmitz H, Tettenborn D, Kruger H, Kohlhepp W. European Multicenter Trial of Nimodipine in the Prophylaxis of Common Migraine (Migraine Without Aura). *Headache*. 1989;29(10):633-8.
561. Frederiksen JL, Larsson HBW, Henriksen O, Olesen J. Magnetic-Resonance-Imaging of the Brain in Patients with Acute Monosymptomatic Optic Neuritis. *Acta Neurologica Scandinavica*. 1989;80(6):512-7.
562. Olesen J, Simonsen K, Nørgaard B, Grønbo M, Johansen OS, Krosgård A, Andersen B. Reproducibility and utility of a simple neurological scoring system for stroke patients (Copenhagen Stroke Scale). *J Neuro Rehab*. 1988(2):59-63.
563. Olesen J. Calcium Entry Blockers in the Treatment of Vertigo. *Annals of the New York Academy of Sciences*. 1988;522:690-7.
564. Larsson HBW, Thomsen C, Frederiksen J, Henriksen O, Olesen J. Chemical-Shift Selective Magnetic-Resonance Imaging of the Optic-Nerve in Patients with Acute Optic Neuritis. *Acta Radiologica*. 1988;29(6):629-32.
565. Larsson HBW, Frederiksen J, Kjaer L, Henriksen O, Olesen J. In vivo Determination of T1 and T2 in the Brain of Patients with Severe But Stable Multiple-Sclerosis. *Magnetic Resonance in Medicine*. 1988;7(1):43-55.
566. Langemark M, Olesen J, Poulsen DL, Bech P. Clinical Characterization of Patients with Chronic Tension Headache. *Headache*. 1988;28(9):590-6.
567. Jensen K, Tuxen C, Olesen J. Pericranial Muscle Tenderness and Pressure-Pain Threshold in the Temporal Region During Common Migraine. *Pain*. 1988;35(1):65-70.
568. Hedman C, Andersen AR, Andersson PG, Gilhus NE, Kangasniemi P, Olsson JE, Strandman E, Nestvold K, Olesen J. Symptoms of classic migraine attacks: modifications brought about by metoprolol. *Cephalalgia*. 1988;8(4):279-84.
569. Andersen AR, Friberg L, Olsen TS, Olesen J. Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomographic demonstration. *ArchNeurol*. 1988;45(2):154-9.
570. Poulsen DL, Hansen HJ, Langemark M, Olesen J, Bech P. Discomfort Or Disability in Patients with Chronic Pain Syndrome. *Psychotherapy and Psychosomatics*. 1987;48(1-4):60-2.
571. Olesen J, Hahn S, Guarente L. Yeast HAP2 and HAP3 activators both bind to the CYC1 upstream activation site, UAS2, in an interdependent manner. *Cell*. 1987;51(6):953-61.
572. Olesen J. The ischemic hypotheses of migraine. *ArchNeurol*. 1987;44(3):321-2.
573. Langemark M, Olesen J. Pericranial tenderness in tension headache. A blind, controlled study. *Cephalalgia*. 1987;7(4):249-55.
574. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache. A double-blind, placebo controlled study. *Headache*. 1987;27(2):90-5.
575. Kangasniemi P, Andersen AR, Andersson PG, Gilhus NE, Hedman C, Hultgren M, Vilming S, Olesen J. Classic migraine: effective prophylaxis with metoprolol. *Cephalalgia*. 1987;7(4):231-8.
576. Hedman C, Andersen AR, Olesen J. Multi-centre versus single-centre trials in migraine. *Neuroepidemiology*. 1987;6(4):190-7.

577. Uddman R, Edvinsson L, Jansen I, Stiernholm P, Jensen K, Olesen J, Sundler F. Peptide-containing nerve fibres in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain? *Pain*. 1986;27(3):391-9.
578. Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. *Cephalalgia*. 1986;6(1):7-14.
579. Olesen J, Jorgensen MB. Leao's spreading depression in the hippocampus explains transient global amnesia. A hypothesis. *Acta NeurolScand*. 1986;73(2):219-20.
580. Olesen J. Beta-adrenergic effects on cerebral circulation. *Cephalalgia*. 1986;6 Suppl 5:41-6.
581. Olesen J. Role of Calcium Entry Blockers in the Prophylaxis of Migraine. *European Neurology*. 1986;25:72-9.
582. Olesen J. Regional cerebral blood flow (rCBF) studies in migraine and epilepsy. *Functional Neurology*. 1986(1):369-74.
583. Larsson H, Frederiksen J, Stigsby B, Olesen J. Evaluation of visual pathways in multiple sclerosis. I. After-images compared to visual evoked potentials. *Acta NeurolScand*. 1986;74(3):195-202.
584. Jensen K, Tfelt-Hansen P, Lauritzen M, Olesen J. Classic migraine. A prospective recording of symptoms. *Acta NeurolScand*. 1986;73(4):359-62.
585. Jensen K, Andersen HO, Olesen J, Lindblom U. Pressure-pain threshold in human temporal region. Evaluation of a new pressure algometer. *Pain*. 1986;25(3):313-23.
586. Jansen I, Uddman R, Hoeherman M, Ekman R, Jensen K, Olesen J, Stiernholm P, Edvinsson L. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. *AnnNeurol*. 1986;20(4):496-501.
587. Frederiksen J, Larsson H, Olesen J, Stigsby B. Evaluation of the visual system in multiple sclerosis. II. Colour vision. *Acta NeurolScand*. 1986;74(3):203-9.
588. Tfelt-Hansen P, Olesen J. Methodological aspects of drug trials in migraine. *Neuroepidemiology*. 1985(4):204-26.
589. Olesen J, Vorstrup S, Lauritzen M. rCBF After Tia and During Migraine Attacks. *Cephalalgia*. 1985;5:43-6.
590. Olesen J, Lauritzen M. Migraine and regional cerebral blood flow. *Nordisk Medicin*. 1985(100):284-5.
591. Olesen J. Migraine and Regional Cerebral Blood-Flow. *Trends in Neurosciences*. 1985;8(7):319-21.
592. Jensen K, Tfelt-Hansen P, Lauritzen M, Olesen J. Clinical trial of nimodipine for single attacks of classic migraine. *Cephalalgia*. 1985;5(3):125-31.
593. Jensen K, Olesen J. Temporal muscle blood flow in common migraine. *Acta NeurolScand*. 1985;72(6):561-70.
594. Bach FW, Jensen K, Blegvad N, Fenger M, Jordal R, Olesen J. Beta-Endorphin and Acth in Plasma During Attacks of Common and Classic Migraine. *Cephalalgia*. 1985;5(3):177-82.
595. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. *Acta NeurolScand*. 1984;69(1):1-8.
596. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. *Cephalalgia*. 1984;4(2):107-11.
597. Olesen J, Lauritzen M. Vascular Aspects of Migraine Patho-Physiology - Regional Cerebral Blood-Flow (Rcbf) During Classical Migraine Attacks. *Munchener Medizinische Wochenschrift*. 1984;126(40):1135-7.
598. Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. *Brain*. 1984;107 ( Pt 2):447-61.
599. Langemark M, Olesen J. Drug abuse in migraine patients. *Pain*. 1984;19(1):81-6.
600. Krabbe AA, Henriksen L, Olesen J. Tomographic determination of cerebral blood flow during attacks of cluster headache. *Cephalalgia*. 1984;4(1):17-23.

601. Edvinsson L, Tfelt-Hansen P, Skarby T, Gjerris F, Olesen J. Presence of alpha-adrenoceptors in human temporal arteries. Comparison between migraine patients and controls. *Cephalalgia*. 1983;3(4):219-24.
602. Tfelt-Hansen P, Jensen K, Vendsborg P, Lauritzen M, Olesen J. Chloromezanone in the treatment of migraine attacks: a double blind comparison with diazepam and placebo. *Cephalalgia*. 1982;2(4):205-10.
603. Tfelt-Hansen P, Eickhoff JH, Olesen J. Mechanism of ergotamine-induced decrease of peripheral systolic blood pressure in man. *Acta PharmacolToxicol(Copenh)*. 1982;51(2):122-5.
604. Tfelt-Hansen P, Eickhoff JH, Olesen J. Duration of the biological effect of ergotamine tartrate. *Adv Neurol*. 1982(33):315-9.
605. Skarby T, Tfelt-Hansen P, Gjerris F, Edvinsson L, Olesen J. Characterization of 5-hydroxytryptamine receptors in human temporal arteries: comparison between migraine sufferers and nonsufferers. *AnnNeurol*. 1982;12(3):272-7.
606. Olesen J, Lauritzen M, Tfelt-Hansen P, Henriksen L, Larsen B. Spreading cerebral oligemia in classical- and normal cerebral blood flow in common migraine. *Headache*. 1982;22(6):242-8.
607. Olesen J. Effects of Circulating Monoamines and Related Substances on rCBF in Man. *Developments in Neuroscience*. 1982;14:183-8.
608. Olesen J. Is Ischemia Involved in the Pathogenesis of Migraine. *Pathologie Biologie*. 1982;30(5):318-24.
609. Lous I, Olesen J. Evaluation of pericranial tenderness and oral function in patients with common migraine, muscle contraction headache and 'combination headache'. *Pain*. 1982;12(4):385-93.
610. Krabbe AA, Olesen J. Effect of histamine on regional cerebral blood flow in man. *Cephalalgia*. 1982;2(1):15-8.
611. Clifford T, Lauritzen M, Bakke M, Olesen J, Moller E. Electromyography of Pericranial Muscles During Treatment of Spontaneous Common Migraine Attacks. *Pain*. 1982;14(2):137-47.
612. Bakke M, Tfelt-Hansen P, Olesen J, Moller E. Action of some pericranial muscles during provoked attacks of common migraine. *Pain*. 1982;14(2):121-35.
613. Tfelt-Hansen P, Olesen J. Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients. *Acta PharmacolToxicol(Copenh)*. 1981;48(1):69-72.
614. Tfelt-Hansen P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine attacks. *Headache*. 1981;21(2):49-54.
615. Olesen J, Tfelt-Hansen P, Henriksen L, Larsen B. The common migraine attack may not be initiated by cerebral ischaemia. *Lancet*. 1981;2(8244):438-40.
616. Olesen J, Larsen B, Lauritzen M. Focal Hyperemia Followed by Spreading Oligemia and Impaired Activation of Rcbf in Classic Migraine. *Annals of Neurology*. 1981;9(4):344-52.
617. Olesen J, Krabbe AA, Tfelt-Hansen P. Methodological aspects of prophylactic drug trials in migraine. *Cephalalgia*. 1981;1(3):127-41.
618. Olesen J. Effect of serotonin on regional cerebral blood flow (rCBF) in man. *Cephalalgia*. 1981;1(1):7-10.
619. Lauritzen M, Trojaborg W, Olesen J. EEG During Attacks of Common and Classical Migraine. *Cephalalgia*. 1981;1(2):63-6.
620. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, Melgaard B, Veilis B. A double blind study of metoclopramide in the treatment of migraine attacks. *Journal of Neurology, Neurosurgery and Psychiatry*. 1980(43):369-71.
621. Tfelt-Hansen P, Olesen J, Lous I. Lignocaine versus saline in migraine pain. *Lancet*. 1980;1(8178):1140.
622. Tfelt-Hansen P, Olesen J. Paracetamol (Acetaminophen) Versus Acetylsalicylic-Acid in Migraine. *European Neurology*. 1980;19(3):163-5.

623. Tfelt-Hansen P, Eickhoff JH, Olesen J. The Effect of Single Dose Ergotamine Tartrate on Peripheral Arteries in Migraine Patients - Methodological Aspects and Time Effect Curve. *Acta Pharmacologica et Toxicologica*. 1980;47(2):151-6.
624. Lauritzen M, Smith T, Fischer-Hansen B, Sparup J, Olesen J. Eaton-Lambert syndrome and malignant thymoma. *Neurology*. 1980;30(6):634-8.
625. Krabbe AA, Olesen J. Ferrum quartz in the prevention of migraine. A double-blind study. *Ugeskrift for laeger*. 1980(142):516-8.
626. Krabbe AA, Olesen J. Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. *Pain*. 1980;8:253-9.
627. Aebelholt Krabbe A, Olesen J. Headache Provocation by Continuous Intravenous-Infusion of Histamine - Clinical-Results and Receptor Mechanisms. *Pain*. 1980;8(2):253-9.
628. Olesen J, Krabbe AA, Veilis B. Experience with 750 migraine patients at a headache clinic. *Ugeskrift for laeger*. 1979(141):2429-33.
629. Olesen J, Henriksen H, Knudsen J, Tfelt-Hansen P. Drug therapy of pain in cancer and terminal illness. *Ugeskrift for laeger*. 1979(141):1819-23.
630. Olesen J, Aebelholt A, Veilis B. The Copenhagen Acute Headache Clinic: organization, patient material and treatment results. *Headache*. 1979;19(4):223-7.
631. Klee JG, Laurtisen B, Olesen J. Parkinsonism and depression treated with electrostimulation (NCE). *Ugeskrift for laeger*. 1979(141):2393-4.
632. Bruhn P, Olesen J, Melgaard B. Controlled trial of EMG feedback in muscle contraction headache. *AnnNeurol*. 1979;6(1):34-6.
633. Sorensen E, Olesen J, Rask-Madsen J, Rask-Andersen H. The electrical potential difference and impedance between CSF and blood in unanesthetized man. *ScandJ ClinLab Invest*. 1978;38(3):203-7.
634. Olesen J, Hougard K, Hertz M. Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man. *Stroke*. 1978;9(4):344-9.
635. Olesen J. Some clinical features of the acute migraine attack. An analysis of 750 patients. *Headache*. 1978;18(5):268-71.
636. Olesen J. Akutklinikker for migr'nepatienter gavner hovedpineforskning og behandling. *Nordisk Medicin*. 1978;8(93,7):169-70.
637. Olesen J. Cluster Headache Associated with Primary Hyperlipidemia. *Acta Neurologica Scandinavica*. 1977;56(5):461-4.
638. Hachinski VC, Olesen J, Norris JW, Larsen B, Enevoldsen E, Lassen NA. Cerebral Hemodynamics in Migraine. *Canadian Journal of Neurological Sciences*. 1977;4(4):245-9.
639. Dige-Petersen H, Noer I, Lassen NA, Tønnesen KH. Subclinical Ergotism. *Lancet*. 1977;July:65-6.
640. Borgesen SE, Sorensen SC, Olesen J, Gjerris F. Spinal tumours associated with increased intracranial pressure. Report of two cases and a discussion on the pathophysiology. *Acta NeurolScand*. 1977;56(3):263-8.
641. Olesen J. Effect of intracarotid prostaglandin E1 on regional cerebral blood flow in man. *Stroke*. 1976;7(6):566-9.
642. Olesen J. Headache clinic in Copenhagen. *Ugeskrift for laeger*. 1976(138):2517-9.
643. Olesen J, Paulson OB. [Medical education in the USA. II. Postgraduate education in specialties or in general practice]. *UgeskrLaeger*. 1974;7:462-5.
644. Olesen J, Paulson OB. Medical education in the USA. I. Medical School Education. *Ugeskrift for laeger*. 1974(4):289-92.
645. Olesen J, Paulson OB. Medical education in the USA. IV. Lifelong continuing education. *Ugeskrift for laeger*. 1974(9):576-8.
646. Olesen J. Methods for measurement of the cerebral blood flow. *Acta NeurolScandSuppl*. 1974;57:1-134.
647. Olesen J. Cerebral Blood Flow. Methods for Measurement Regulation, Effects of Drugs and Changes in Disease. *Acta Neurologica Scandinavica*. 1974;50(Suppl. 57):1-134.

648. Olesen J. Medical education in the USA. III. A concrete example of specialist education: Neurology. *Ugeskrift for læger*. 1974(2):520-2.
649. Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of Brain Circulation in Severe Arterial Hypertension. *British Medical Journal*. 1973;1(5852):507-10.
650. Skinhoj E, Olesen J, Paulson OB. Influence of smoking and nicotine on cerebral blood flow and metabolic rate of oxygen in man. *JApplPhysiol*. 1973;35(6):820-2.
651. Paulson OB, Parving HH, Olesen J, Skinhoj E. Influence of carbon monoxide and of hemodilution on cerebral blood flow and blood gases in man. *JApplPhysiol*. 1973;35(1):111-6.
652. Olesen J. Quantitative evaluation of normal and pathologic cerebral blood flow regulation to perfusion pressure. Changes in man. *ArchNeurol*. 1973;28(3):143-9.
653. Christensen MS, Paulson OB, Olesen J, Alexander SC, Skinhoj E, Dam WH, Lassen NA. Cerebral apoplexy (stroke) treated with or without prolonged artificial hyperventilation. 1. Cerebral circulation, clinical course, and cause of death. *Stroke*. 1973;4(4):568-631.
654. Wahl M, Thureau K, Bosse O, Kuschins W, Lassen NA, Ingvar DH, Michaeli J, Olesen J. Effect of I-Norepinephrine on Diameter of Pial Arterioles and Arteries in Cat. *Circulation Research*. 1972;31(2):248-56.
655. Paulson OB, Olesen J, Christensen MS. Restoration of autoregulation of cerebral blood flow by hypocapnia. *Neurology*. 1972;22(3):286-93.
656. Olesen J, Skinhoj E, Strandga SV. Tolerance of Cerebral Circulation to Changes in Blood-Pressure - Implications for Treatment of Patients with Arterial Hypertension. *Acta Neurologica Scandinavica*. 1972;48:481-&.
657. Olesen J, Skinhoj E. Effects of Ergot Alkaloids (Hydergine) on Cerebral Hemodynamics in Man. *Acta Pharmacologica et Toxicologica*. 1972;31(1-2):75-85.
658. Olesen J. The effect of intracarotid epinephrine, norepinephrine, and angiotensin on the regional cerebral blood flow in man. *Neurology*. 1972;22(9):978-87.
659. Heilbrun MP, Olesen J, Lassen NA. Regional Cerebral Blood-Flow Studies in Subarachnoid Hemorrhage. *Journal of Neurosurgery*. 1972;37(1):36-44.
660. Wahl M, Thureau K, Ingvar DH, Bosse O, Kuschins W, Lassen NA, Olesen J. Adrenergic Control of Cerebral Vascular-Resistance - Micropuncture Study. *European Neurology*. 1971;6(1-6):185-9.
661. Simard D, Olesen J, Paulson OB, Lassen NA, Skinhoj E. Regional Cerebral Blood Flow and Its Regulation in Dementia. *Brain*. 1971;94:273-88.
662. Olesen J, Paulson OB, Lassen NA. Regional cerebral blood flow in man determined by the initial slope of the clearance of intra-arterially injected <sup>133</sup>Xe. *Stroke*. 1971(2):519-40.
663. Olesen J, Paulson OB. The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumor. *Stroke*. 1971;2(2):148-59.
664. Olesen J. Contralateral Focal Increase of Cerebral Blood Flow in Man During Arm Work. *Brain*. 1971;94:635-46.
665. Olesen J. Influences of Certain Vasoactive Amines on Regional Cerebral Blood Flow in Man. *Headache*. 1971;11(2):91-&.
666. Lassen NA, Trap-Jensen J, Alexander SC, Olesen J, Paulson OB. Blood-brain barrier studies in man using the double-indicator method. *AmJPhysiol*. 1971;220(6):1627-33.
667. Boysen G, Ladegaard-Pedersen HJ, Henriksen H, Olesen J, Paulson OB, Engell HC. The effects of PaCO<sub>2</sub> on regional cerebral blood flow and internal carotid arterial pressure during carotid clamping. *Anesthesiology*. 1971;35(3):286-300.
668. Olesen J. Total Co<sub>2</sub>, lactate, and pyruvate in brain biopsies taken after freezing the tissue in situ. *Acta NeurolScand*. 1970;46(2):141-8.
669. Olesen J, Videbaek A. Chronic myelogenous leukemia. Results of therapy with busulfan. *Nordisk Medicin*. 1969(82):1284-90.